1
|
Chen LP, Zhang LF, Liu S, Hua H, Zhang L, Liu BC, Wang RR. Ling-Gui-Zhu-Gan decoction ameliorates nonalcoholic fatty liver disease via modulating the gut microbiota. Microbiol Spectr 2024:e0197923. [PMID: 38647315 DOI: 10.1128/spectrum.01979-23] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/12/2023] [Accepted: 02/27/2024] [Indexed: 04/25/2024] Open
Abstract
Numerous studies have supported that nonalcoholic fatty liver disease (NAFLD) is highly associated with gut microbiota dysbiosis. Ling-Gui-Zhu-Gan decoction (LG) has been clinically used to treat NAFLD, but the underlying mechanism remains unknown. This study investigated the therapeutic effect and mechanisms of LG in mice with NAFLD induced by a high-fat diet (HD). An HD-induced NAFLD mice model was established to evaluate the efficacy of LG followed by biochemical and histopathological analysis. Metagenomics, metabolomics, and transcriptomics were used to explore the structure and metabolism of the gut microbiota. LG significantly improved hepatic function and decreased lipid droplet accumulation in HD-induced NAFLD mice. LG reversed the structure of the gut microbiota that is damaged by HD and improved intestinal barrier function. Meanwhile, the LG group showed a lower total blood bile acids (BAs) concentration, a shifted BAs composition, and a higher fecal short-chain fatty acids (SCFAs) concentration. Furthermore, LG could regulate the hepatic expression of genes associated with the primary BAs biosynthesis pathway and peroxisome proliferator-activated receptor (PPAR) signaling pathway. Our study suggested that LG could ameliorate NAFLD by altering the structure and metabolism of gut microbiota, while BAs and SCFAs are considered possible mediating substances. IMPORTANCE Until now, there has still been no study on the gut microbiota and metabolomics of Ling-Gui-Zhu-Gan decoction (LG) in nonalcoholic fatty liver disease (NAFLD) mouse models. Our study is the first to report on the reshaping of the structure and metabolism of the gut microbiota by LG, as well as explore the potential mechanism underlying the improvement of NAFLD. Specifically, our study demonstrates the potential of gut microbial-derived short-chain fatty acids (SCFAs) and blood bile acids (BAs) as mediators of LG therapy for NAFLD in animal models. Based on the results of transcriptomics, we further verified that LG attenuates NAFLD by restoring the metabolic disorder of BAs via the up-regulation of Fgf15/FXR in the ileum and down-regulation of CYP7A1/FXR in the liver. LG also reduces lipogenesis in NAFLD mice by mediating the peroxisome proliferator-activated receptor (PPAR) signaling pathway, which then contributes to reducing hepatic inflammation and improving intestinal barrier function to treat NAFLD.
Collapse
Affiliation(s)
- Lu-Ping Chen
- Shanghai Innovation Center of TCM Health Service, Shanghai University of Traditional Chinese Medicine, Shanghai, China
| | - Lin-Fang Zhang
- Shanghai Innovation Center of TCM Health Service, Shanghai University of Traditional Chinese Medicine, Shanghai, China
- Oxford Suzhou Centre for Advanced Research, Suzhou Industrial Park, Jiangsu, China
| | - Shuang Liu
- Shanxi Institute for Function Food, Shanxi Agricultural University, Taiyuan, Shanxi, China
| | - Hua Hua
- Sichuan Institute for Translational Chinese Medicine, Chengdu, China
- Sichuan Academy of Chinese Medical Sciences, Chengdu, China
| | - Lei Zhang
- Shanghai Innovation Center of TCM Health Service, Shanghai University of Traditional Chinese Medicine, Shanghai, China
| | - Bao-Cheng Liu
- Shanghai Innovation Center of TCM Health Service, Shanghai University of Traditional Chinese Medicine, Shanghai, China
| | - Rui-Rui Wang
- Shanghai Innovation Center of TCM Health Service, Shanghai University of Traditional Chinese Medicine, Shanghai, China
| |
Collapse
|
2
|
Chen F, Zhang Y, Peng P, Huang XT, Qiu ZH, Liu BC, Yang TL, Yang B, Guo Y. Isolation and culture of human primary osteoblasts: Comparing the effects of differences in method details on osteoblast characteristics. Genes Dis 2024; 11:546-549. [PMID: 37692490 PMCID: PMC10491899 DOI: 10.1016/j.gendis.2023.03.024] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/03/2022] [Revised: 03/19/2023] [Accepted: 03/20/2023] [Indexed: 09/12/2023] Open
Affiliation(s)
- Fei Chen
- Key Laboratory of Biomedical Information Engineering of Ministry of Education, Biomedical Informatics & Genomics Center, School of Life Science and Technology, Xi'an Jiaotong University, Xi'an, Shaanxi 710049, China
| | - Yan Zhang
- Key Laboratory of Biomedical Information Engineering of Ministry of Education, Biomedical Informatics & Genomics Center, School of Life Science and Technology, Xi'an Jiaotong University, Xi'an, Shaanxi 710049, China
| | - Pai Peng
- Key Laboratory of Biomedical Information Engineering of Ministry of Education, Biomedical Informatics & Genomics Center, School of Life Science and Technology, Xi'an Jiaotong University, Xi'an, Shaanxi 710049, China
| | - Xiao-Ting Huang
- Key Laboratory of Biomedical Information Engineering of Ministry of Education, Biomedical Informatics & Genomics Center, School of Life Science and Technology, Xi'an Jiaotong University, Xi'an, Shaanxi 710049, China
| | - Zi-Han Qiu
- Key Laboratory of Biomedical Information Engineering of Ministry of Education, Biomedical Informatics & Genomics Center, School of Life Science and Technology, Xi'an Jiaotong University, Xi'an, Shaanxi 710049, China
| | - Bao-Cheng Liu
- Department of Orthopaedics, Shannxi Provincial People's Hospital (The Third Affiliated Hospital of Xi'an Jiaotong University), Xi'an, Shaanxi 710068, China
| | - Tie-Lin Yang
- Key Laboratory of Biomedical Information Engineering of Ministry of Education, Biomedical Informatics & Genomics Center, School of Life Science and Technology, Xi'an Jiaotong University, Xi'an, Shaanxi 710049, China
| | - Bo Yang
- Department of Orthopaedics, Shannxi Provincial People's Hospital (The Third Affiliated Hospital of Xi'an Jiaotong University), Xi'an, Shaanxi 710068, China
| | - Yan Guo
- Key Laboratory of Biomedical Information Engineering of Ministry of Education, Biomedical Informatics & Genomics Center, School of Life Science and Technology, Xi'an Jiaotong University, Xi'an, Shaanxi 710049, China
| |
Collapse
|
3
|
Wang KJ, Xia QD, Ding F, Hu X, Liu BC. [Pulmonary nuclear protein of the testis midline carcinoma:a case report]. Zhonghua Jie He He Hu Xi Za Zhi 2023; 46:1019-1021. [PMID: 37752046 DOI: 10.3760/cma.j.cn112147-20230316-00134] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Subscribe] [Scholar Register] [Indexed: 09/28/2023]
Abstract
Nuclear protein of the testis (NUT) midline carcinoma (NMC) is a rare malignant epithelial tumor that typically occurs in the midline regions such as the head, neck, and mediastinum. This tumor is characterized by rapid development, aggressive growth, and strong invasiveness. Due to its short duration, most patients are diagnosed at advanced stages, often leading to rapid mortality. Although reports on pulmonary NUT carcinoma are uncommon, this article presents a case of pulmonary NUT carcinoma in which the patient repeatedly expectorated bronchial casts and tumor tissue. Additionally, a comprehensive review of relevant literature from recent years is provided to enhance understanding of this disease.
Collapse
Affiliation(s)
- K J Wang
- Bishan Hospital Afflicted of Chongqing Medical University, Chongqing 402260, China
| | - Q D Xia
- Bishan Hospital Afflicted of Chongqing Medical University, Chongqing 402260, China
| | - F Ding
- Bishan Hospital Afflicted of Chongqing Medical University, Chongqing 402260, China
| | - X Hu
- Bishan Hospital Afflicted of Chongqing Medical University, Chongqing 402260, China
| | - B C Liu
- Bishan Hospital Afflicted of Chongqing Medical University, Chongqing 402260, China
| |
Collapse
|
4
|
Yang M, Hou SM, Yuan L, Wang M, Zheng J, Lu KQ, Yan Y, Zhang SY, Li M, Cao JY, Yang M, Zhang XL, Liu H, Liu BC, Wang Y, Wang B. [The consistency of skeletal muscle mass measured by CT at L 1 and L 3 levels and the correlation of skeletal muscle density at L 1 level with prognosis in dialysis patients]. Zhonghua Yi Xue Za Zhi 2023; 103:2850-2858. [PMID: 37726991 DOI: 10.3760/cma.j.cn112137-20230608-00970] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Subscribe] [Scholar Register] [Indexed: 09/21/2023]
Abstract
Objective: To investigate the consistency of skeletal muscle mass by CT at 1st lumbar vertebrae (L1) and 3rd lumbar vertebrae (L3) levels and the correlation of skeletal muscle density (SMD) at L1 level with prognosis in dialysis patients. Methods: A total of 1 020 patients who underwent initial dialysis and had CT examination data in four centers (Zhongda Hospital Affiliated to Southeast University, the Third Affiliated Hospital of Soochow University, Taizhou People's Hospital Affiliated to Nanjing Medical University and the Affiliated Hospital of Yangzhou University) from January 2014 to December 2019 were retrospectively collected. The skeletal muscle index (SMI) and SMD at L1 and L3 CT images were measured and calculated in patients with both L1 and L3 level CT images. The consistency of SMI and SMD at L1 and L3 levels was analyzed, and the cut-off value of SMI and SMD at L1 level for predicting all-cause mortality and their correlation with the prognosis of dialysis patients were studied. Cox regression model was used to analyze the risk factors for all-cause death and cardiac death. Results: A total of 383 patients had both L1 and L3 level images, including 233 males and 150 females. The average SMD value of 16 samples (4.2%) exceeded the 95% consistency limit range (-8.71 to 7.75 HU), and the average SMI value of 15 samples (3.9%) exceeded the 95% consistency limit range (-20.45 to 9.53 HU). The optimal cut-off value of SMD at L1 level for predicting all-cause mortality was 36.46 HU and the area under curve (AUC) of receiver operating characteristic (ROC) curve was 0.658 (95%CI: 0.596-0.721, P<0.001), with the sensitivity and specificity of 83.8% and 57.5%, respectively. SMI at L1 level was not significantly associated with all-cause mortality (P=0.299). Multivariate Cox regression analysis showed that low SMD at L1 level was associated with all-cause mortality (HR=2.861, 95%CI: 1.576-5.193, P=0.001) and cardiac death (HR=3.771, 95%CI:1.462-9.724, P=0.006). Conclusions: SMD at L1 levelis consistent with SMD at L3 level and can be used to evaluate muscle mass. Low SMD is a risk factor for mortality in dialysis patients.
Collapse
Affiliation(s)
- M Yang
- Department of Nephrology, Affiliated Hospital of Yangzhou University, Yangzhou 225001, China
| | - S M Hou
- Institute of Nephrology, Zhongda Hospital Affiliated to Southeast University, Nanjing 210009, China
| | - L Yuan
- Department of Nephrology, Affiliated Hospital of Yangzhou University, Yangzhou 225001, China
| | - M Wang
- Department of Nephrology, Affiliated Hospital of Yangzhou University, Yangzhou 225001, China
| | - J Zheng
- Institute of Nephrology, Zhongda Hospital Affiliated to Southeast University, Nanjing 210009, China
| | - K Q Lu
- Institute of Nephrology, Zhongda Hospital Affiliated to Southeast University, Nanjing 210009, China
| | - Y Yan
- Institute of Nephrology, Zhongda Hospital Affiliated to Southeast University, Nanjing 210009, China
| | - S Y Zhang
- Department of Nephrology, Taizhou People's Hospital Affiliated to Nanjing Medical University, Taizhou 225300, China
| | - M Li
- Department of Nephrology, the Third Affiliated Hospital of Soochow University, Changzhou 213000, China
| | - J Y Cao
- Department of Nephrology, Taizhou People's Hospital Affiliated to Nanjing Medical University, Taizhou 225300, China
| | - M Yang
- Department of Nephrology, Affiliated Hospital of Yangzhou University, Yangzhou 225001, China
| | - X L Zhang
- Institute of Nephrology, Zhongda Hospital Affiliated to Southeast University, Nanjing 210009, China
| | - H Liu
- Institute of Nephrology, Zhongda Hospital Affiliated to Southeast University, Nanjing 210009, China
| | - B C Liu
- Institute of Nephrology, Zhongda Hospital Affiliated to Southeast University, Nanjing 210009, China
| | - Y Wang
- Department of Nephrology, Affiliated Hospital of Yangzhou University, Yangzhou 225001, China
| | - B Wang
- Institute of Nephrology, Zhongda Hospital Affiliated to Southeast University, Nanjing 210009, China
| |
Collapse
|
5
|
Zhang XS, Liu BC, Du X, Zhang YL, Xu N, Liu XL, Li WM, Lin H, Liang R, Chen CY, Huang J, Yang YF, Zhu HL, Pan L, Wang XD, Li GH, Liu ZG, Zhang YQ, Liu ZF, Hu JD, Liu CS, Li F, Yang W, Meng L, Han YQ, Lin LE, Zhao ZY, Tu CQ, Zheng CF, Bai YL, Zhou ZP, Chen SN, Qiu HY, Yang LJ, Sun XL, Sun H, Zhou L, Liu ZL, Wang DY, Guo JX, Pang LP, Zeng QS, Suo XH, Zhang WH, Zheng YJ, Jiang Q. [To compare the efficacy and incidence of severe hematological adverse events of flumatinib and imatinib in patients newly diagnosed with chronic phase chronic myeloid leukemia]. Zhonghua Xue Ye Xue Za Zhi 2023; 44:728-736. [PMID: 38049316 PMCID: PMC10630575 DOI: 10.3760/cma.j.issn.0253-2727.2023.09.005] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Subscribe] [Scholar Register] [Received: 03/28/2023] [Indexed: 12/06/2023]
Abstract
Objective: To analyze and compare therapy responses, outcomes, and incidence of severe hematologic adverse events of flumatinib and imatinib in patients newly diagnosed with chronic phase chronic myeloid leukemia (CML) . Methods: Data of patients with chronic phase CML diagnosed between January 2006 and November 2022 from 76 centers, aged ≥18 years, and received initial flumatinib or imatinib therapy within 6 months after diagnosis in China were retrospectively interrogated. Propensity score matching (PSM) analysis was performed to reduce the bias of the initial TKI selection, and the therapy responses and outcomes of patients receiving initial flumatinib or imatinib therapy were compared. Results: A total of 4 833 adult patients with CML receiving initial imatinib (n=4 380) or flumatinib (n=453) therapy were included in the study. In the imatinib cohort, the median follow-up time was 54 [interquartile range (IQR), 31-85] months, and the 7-year cumulative incidences of CCyR, MMR, MR(4), and MR(4.5) were 95.2%, 88.4%, 78.3%, and 63.0%, respectively. The 7-year FFS, PFS, and OS rates were 71.8%, 93.0%, and 96.9%, respectively. With the median follow-up of 18 (IQR, 13-25) months in the flumatinib cohort, the 2-year cumulative incidences of CCyR, MMR, MR(4), and MR(4.5) were 95.4%, 86.5%, 58.4%, and 46.6%, respectively. The 2-year FFS, PFS, and OS rates were 80.1%, 95.0%, and 99.5%, respectively. The PSM analysis indicated that patients receiving initial flumatinib therapy had significantly higher cumulative incidences of CCyR, MMR, MR(4), and MR(4.5) and higher probabilities of FFS than those receiving the initial imatinib therapy (all P<0.001), whereas the PFS (P=0.230) and OS (P=0.268) were comparable between the two cohorts. The incidence of severe hematologic adverse events (grade≥Ⅲ) was comparable in the two cohorts. Conclusion: Patients receiving initial flumatinib therapy had higher cumulative incidences of therapy responses and higher probability of FFS than those receiving initial imatinib therapy, whereas the incidence of severe hematologic adverse events was comparable between the two cohorts.
Collapse
Affiliation(s)
- X S Zhang
- Peking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing 100044, China
| | - B C Liu
- National Clinical Research Center for Blood Diseases, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin 300020, China
| | - X Du
- The Second People's Hospital of Shenzhen, Shenzhen 518035, China
| | - Y L Zhang
- Henan Cancer Hospital, The Affiliated Cancer Hospital of Zhengzhou University, Zhengzhou 450008, China
| | - N Xu
- Nanfang Hospital, Southern Medical University, Guangzhou 510515, China
| | - X L Liu
- Nanfang Hospital, Southern Medical University, Guangzhou 510515, China
| | - W M Li
- Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, China
| | - H Lin
- First Hospital of Jilin University, Changchun 130021, China
| | - R Liang
- Xijing Hospital, Airforce Military Medical University, Xi'an 710032, China
| | - C Y Chen
- Qilu Hospital of Shandong University, Jinan 250012, China
| | - J Huang
- The Fourth Affiliated Hospital of Zhejiang University, Hangzhou 322000, China
| | - Y F Yang
- Institute of Hematology, West China Hospital, Sichuan University, Chengdu 610041, China
| | - H L Zhu
- Institute of Hematology, West China Hospital, Sichuan University, Chengdu 610041, China
| | - L Pan
- Institute of Hematology, West China Hospital, Sichuan University, Chengdu 610041, China
| | - X D Wang
- Sichuan Academy of Medical Sciences Sichuan Provincial People's Hospital, Chengdu 610072, China
| | - G H Li
- Xi'an International Medical Center Hospital, Xi'an 710038, China
| | - Z G Liu
- Shengjing Hospital of China Medical University, Shenyang 110020, China
| | - Y Q Zhang
- The Second Affiliated Hospital of Harbin Medical University, Harbin 150086, China
| | - Z F Liu
- The First Affiliated Hospital of Guangxi Medical University, Nanning 530021, China
| | - J D Hu
- Fujian Medical University Union Hospital, Fuzhou 350001, China
| | - C S Liu
- First Hospital of Jilin University, Changchun 130021, China
| | - F Li
- The First Affiliated Hospital of Nanchang University, Nanchang 330006, China
| | - W Yang
- Shengjing Hospital of China Medical University, Shenyang 110020, China
| | - L Meng
- Tongji Hospital of Tongji Medical College, Tongji Medical College of Huazhong University of Science and Technology, Wuhan 430030, China
| | - Y Q Han
- The Affiliated Hospital of Inner Mongolia Medical University, Hohhot 010050, China
| | - L E Lin
- Hainan General Hospital, Haikou 570311, China
| | - Z Y Zhao
- Hainan General Hospital, Haikou 570311, China
| | - C Q Tu
- Shenzhen Baoan Hospital, Shenzhen University Second Affiliated Hospital, Shenzhen 518101, China
| | - C F Zheng
- Shenzhen Baoan Hospital, Shenzhen University Second Affiliated Hospital, Shenzhen 518101, China
| | - Y L Bai
- Henan Provincial People's Hospital, Zhengzhou University People's Hospital, Zhengzhou 450003, China
| | - Z P Zhou
- The Second Hospital Affiliated to Kunming Medical University, Kunming 650106, China
| | - S N Chen
- National Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, Institute of Blood and Marrow Transplantation of Soochow University, Suzhou 215006, China
| | - H Y Qiu
- National Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, Institute of Blood and Marrow Transplantation of Soochow University, Suzhou 215006, China
| | - L J Yang
- Xi'an International Medical Center Hospital, Xi'an 710117, China
| | - X L Sun
- The First Affiliated Hospital of Dalian Medical University, Dalian 116011, China
| | - H Sun
- The First Affiliated Hospital of Zhengzhou University, Zhengzhou 450000, China
| | - L Zhou
- Shanghai Institute of Hematology, State Key Laboratory of Medical Genomics, National Research Center for Translational Medicine at Shanghai, Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai 200025, China
| | - Z L Liu
- Huazhong University of Science and Technology Union Shenzhen Hospital, Nanshan Hospital, Shenzhen 518000, China
| | - D Y Wang
- Huazhong University of Science and Technology Union Shenzhen Hospital, Nanshan Hospital, Shenzhen 518000, China
| | - J X Guo
- The Second Affiliated Hospital of Fujian Medical University, Quanzhou 362000, China
| | - L P Pang
- Peking University Shenzhen Hospital, Shenzhen 516473, China
| | - Q S Zeng
- The First Affiliated Hospital of Anhui Medical University, Hefei 230022, China
| | - X H Suo
- Handan Central Hospital, Handan 057150, China
| | - W H Zhang
- First Hospital of Shangxi Medical University, Taiyuan 300012, China
| | - Y J Zheng
- First Hospital of Shangxi Medical University, Taiyuan 300012, China
| | - Q Jiang
- Peking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing 100044, China
| |
Collapse
|
6
|
Ai LL, Lai AL, Qin XH, Liu BC, Li J, Wang JX, Zhu P. [Application and clinical significance of intercellular proximity labeling technique in chronic myelogenous leukemia]. Zhonghua Xue Ye Xue Za Zhi 2023; 44:543-549. [PMID: 37749032 PMCID: PMC10509616 DOI: 10.3760/cma.j.issn.0253-2727.2023.07.003] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Subscribe] [Scholar Register] [Received: 03/30/2023] [Indexed: 09/27/2023]
Abstract
Objective: This study aimed to explore the application of interaction-dependent fucosyl-biotinylation (FucoID), a chemical biology-based proximity labeling technique, in capturing tumor antigen-specific T cells and its clinical value in chronic myelogenous leukemia (CML) . Methods: Flow cytometry and fluorescence microscopy were employed to evaluate the experimental parameters for FucoID in CML. Peripheral blood samples were obtained from 14 newly diagnosed CML patients in the chronic phase. These samples underwent flow cytometry-based sorting and were subsequently labeled with FucoID to facilitate the isolation of tumor cells and T cells, followed by the immunophenotypic identification of tumor antigen-specific T cells. Finally, the diagnostic and therapeutic potential of FucoID in CML was assessed. Results: Initially, the experimental parameters for FucoID in CML were established. The proportion of CD3(+) T cells in patients was (8.96±6.47) %, exhibiting a marked decrease compared with that in healthy individuals at (38.89±22.62) %. The proportion of tumor-specific antigen-reactive T cells was (3.34±4.49) %, which demonstrated interpatient variability. In addition, the proportion of tumor-specific antigen-active T cells in CD4(+) T cells was (3.95±1.72) %, which was generally lower than the proportion in CD8(+) T cells at (5.68±2.18) %. Compared with those in tumor-specific antigen-nonreactive T cells, CCR7(-)CD45RA(-) effector memory T cells and CCR7(-)CD45RA(+) effector T cells were highly enriched in tumor-specific antigen-reactive T cells. Moreover, the intensity of tumor immune reactivity in patients exhibited a significant correlation with white blood cell count (WBC) and hemoglobin (HGB) levels in peripheral blood, while no such correlation was observed with other clinical baseline characteristics. Conclusion: The combination of FucoID and flow cytometry enables the rapid identification and isolation of tumor antigen-specific T cells in CML. The successful application of this method in CML and the implications of our findings suggest its potential clinical value in the field of hematologic malignancies.
Collapse
Affiliation(s)
- L L Ai
- State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin 300020, China Tianjin Institutes of Health Science, Tianjin 301600, China
| | - A L Lai
- State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin 300020, China Tianjin Institutes of Health Science, Tianjin 301600, China
| | - X H Qin
- State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin 300020, China Tianjin Institutes of Health Science, Tianjin 301600, China
| | - B C Liu
- State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin 300020, China Tianjin Institutes of Health Science, Tianjin 301600, China
| | - J Li
- State Key Laboratory of Coordination Chemistry, Chemistry and Biomedicine Innovation Center (ChemBIC), School of Chemistry and Chemical Engineering, Nanjing University, Nanjing 210023, China
| | - J X Wang
- State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin 300020, China Tianjin Institutes of Health Science, Tianjin 301600, China
| | - P Zhu
- State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin 300020, China Tianjin Institutes of Health Science, Tianjin 301600, China
| |
Collapse
|
7
|
Wang HY, Liu BC. [Exploration and expectation of magnetic resonance imaging in the evaluation of prostate cancer]. Zhonghua Yi Xue Za Zhi 2023; 103:1435-1438. [PMID: 37198104 DOI: 10.3760/cma.j.cn112137-20230302-00317] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Grants] [Subscribe] [Scholar Register] [Indexed: 05/19/2023]
Abstract
With the progress of imaging technology, magnetic resonance imaging (MRI) has become the preferred imaging method for prostate cancer due to its excellent soft tissue resolution and the capability of multiparametric and multi-planar imaging. This paper briefly describes the current application and research progress of MRI in the preoperative qualitative diagnosis, staging assessment and postoperative recurrence monitoring of prostate cancer. The purpose is to deepen the understanding of clinicians and radiologists on the value of MRI in prostate cancer, and to promote the exploration of MRI in the management of prostate cancer.
Collapse
Affiliation(s)
- H Y Wang
- Department of Radiology, First Medical Center, Chinese PLA General Hospital, Beijing 100853, China
| | - B C Liu
- Department of Radiology, First Medical Center, Chinese PLA General Hospital, Beijing 100853, China
| |
Collapse
|
8
|
Liu BC, Wang HY, Dong Z, Zhang Y, Bai X, Ding XH, Zhang XJ, Xu W, Zhao J, Hao YW, Ye HY. [Diagnostic value of multiparametric MRI-based models in the assessment of extra-prostatic extension of prostate cancer]. Zhonghua Yi Xue Za Zhi 2023; 103:1439-1445. [PMID: 37198105 DOI: 10.3760/cma.j.cn112137-20221215-02656] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Grants] [Subscribe] [Scholar Register] [Indexed: 05/19/2023]
Abstract
Objective: To evaluate the diagnostic value of multiparametric magnetic resonance imaging (mpMRI) based models in the assessment of extra-prostatic extension (EPE) of prostate cancer. Methods: This retrospective study included 168 consecutive men with prostate cancers [aged 48 to 82 (66.6±6.8) years] who underwent radical prostatectomy and preoperative mpMRI examinations at the First Medical Center of the PLA General Hospital from January 2021 to February 2022. According to European Society of Urogenital Radiology (ESUR) score, EPE grade and mEPE score, all cases were independently evaluated by two radiologists, with disagreement reviewed by a senior radiologist as the final result. The diagnostic performance of each MRI-based model for pathologic EPE prediction was assessed using receiver operating characteristic curve (ROC), and the differences between the corresponding area under the curve (AUC) were compared using the DeLong test. The weighted Kappa test was used to evaluate the inter-reader agreement of each MRI-based model. Results: A total of 62 (36.9%) prostate cancer patients had pathologic confirmed EPE after radical prostatectomy. The AUC of ESUR score, EPE grade and mEPE score for predicting pathologic EPE were 0.836 (95%CI: 0.771-0.888), 0.834 (95%CI: 0.769-0.887) and 0.785 (95%CI: 0.715-0.844), respectively. The AUC of ESUR score and EPE grade were both superior to that of mEPE score with significant differences (all P<0.05), while there was no significant difference between the ESUR score and EPE grade models (P=0.900). EPE grading and mEPE score had good inter-reader consistency, with weighted Kappa values of 0.65 (95%CI: 0.56-0.74) and 0.74 (95%CI: 0.64-0.84), respectively. The inter-reader consistency of ESUR score was moderate, and the weighted Kappa value was 0.52 (95%CI: 0.40-0.63). Conclusion: All MRI-based models showed good preoperative diagnostic value in predicting EPE, among which the EPE grade resulted in more reliable performance with substantial inter-reader agreement.
Collapse
Affiliation(s)
- B C Liu
- Department of Radiology, the First Medical Center of Chinese PLA General Hospital, Beijing 100853, China
| | - H Y Wang
- Department of Radiology, the First Medical Center of Chinese PLA General Hospital, Beijing 100853, China
| | - Z Dong
- Department of Radiology, the Sixth Medical Center of Chinese PLA General Hospital, Beijing 100048, China
| | - Y Zhang
- Department of Radiology, the Sixth Medical Center of Chinese PLA General Hospital, Beijing 100048, China
| | - X Bai
- Department of Radiology, the First Medical Center of Chinese PLA General Hospital, Beijing 100853, China
| | - X H Ding
- Department of Pathology, the First Medical Center of Chinese PLA General Hospital, Beijing 100853, China
| | - X J Zhang
- Department of Radiology, the First Medical Center of Chinese PLA General Hospital, Beijing 100853, China
| | - W Xu
- Department of Radiology, the First Medical Center of Chinese PLA General Hospital, Beijing 100853, China
| | - J Zhao
- Department of Radiology, the First Medical Center of Chinese PLA General Hospital, Beijing 100853, China
| | - Y W Hao
- Department of Radiology, the First Medical Center of Chinese PLA General Hospital, Beijing 100853, China
| | - H Y Ye
- Department of Radiology, the First Medical Center of Chinese PLA General Hospital, Beijing 100853, China
| |
Collapse
|
9
|
Cui MQ, He B, Xu W, Hao YW, Ding XH, Wang S, Bai X, Liu BC, Ye HY, Wang HY. [Value of clear cell likelihood score in differentiation between renal oncocytoma and clear cell renal cell carcinoma]. Zhonghua Yi Xue Za Zhi 2022; 102:3779-3785. [PMID: 36517429 DOI: 10.3760/cma.j.cn112137-20221020-02193] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/17/2023]
Abstract
Objective: To evaluate the value of clear cell likelihood score (ccLS) in identifying renal oncocytoma (RO) and clear cell renal cell carcinoma (ccRCC). Methods: Retrospective data of pathologically confirmed 43 RO patients [24 men and 19 women, aged 22-77 (54±14) years] between February 2008 and September 2021 and 43 ccRCC patients [30 men and 13 women, aged 29-78 (56±12) years] between May and July 2021 were consecutively included in the department of radiology, Chinese PLA General Hospital. Two radiologists used ccLS to assess each case independently, and disagreements were resolved by consensus. The ability of ccLS to identify RO and ccRCC was examined by the receiver operating characteristic (ROC) curve which identified the best optimal diagnostic cut-off values, sensitivity, specificity, accuracy, positive predictive value, and negative predictive value. Results: The mean tumor diameter was 3.8 cm in RO patients and 3.7 cm in ccRCC patients. Central scar and segmental enhancement inversion (SEI) were more frequently observed in the RO group compared to the ccRCC group [53.5% (23∶43) versus 11.6% (5∶43) and 41.9% (18∶43) versus 7.0% (3∶43), respectively], with statistical differences (P<0.001). The ccLS scores in the RO group ranged from 1 to 4, while 79.0% of the cases were 3. The ccLS scores in the ccRCC group ranged from 2 to 5, while 72% of the cases were 4. The scores of the two groups were statistically different (P<0.001). The ccLS showed the best performance when the threshold was 4 according to the ROC curve. The sensitivity, specificity, accuracy, positive predictive value, and negative predictive value of ccLS for distinguishing RO from ccRCC were 83.7%, 90.7%, 87.2%, 90.0%, and 84.8%, respectively, and the area under the ROC curve value was 0.879. Conclusion: The ccLS has credible sensitivity and specificity in differentiating renal oncocytoma from clear cell carcinoma, which may be helpful for the preoperative diagnosis.
Collapse
Affiliation(s)
- M Q Cui
- Medical School of Chinese PLA, Beijing 100853, China
| | - B He
- Department of Radiology, Zibo Centre Hospital, Zibo 255036, China
| | - W Xu
- Department of Radiology, the First Medical Centre, PLA General Hospital, Beijing 100853, China
| | - Y W Hao
- Medical School of Chinese PLA, Beijing 100853, China
| | - X H Ding
- Department of Pathology, the First Medical Centre, PLA General Hospital, Beijing 100853, China
| | - S Wang
- Department of Radiology, the First Medical Centre, PLA General Hospital, Beijing 100853, China
| | - X Bai
- Department of Radiology, the Fifth Medical Centre, PLA General Hospital, Beijing 100039, China
| | - B C Liu
- Medical School of Chinese PLA, Beijing 100853, China
| | - H Y Ye
- Department of Radiology, the First Medical Centre, PLA General Hospital, Beijing 100853, China
| | - H Y Wang
- Department of Radiology, the First Medical Centre, PLA General Hospital, Beijing 100853, China
| |
Collapse
|
10
|
An XY, Hu LX, Li M, Liu BC, Wang RQ, Nan YM. [A study on treatment timing selection and short-term efficacy prediction with changes in cytokine levels before and after non-biological artificial liver treatment in acute-on-chronic liver failure]. Zhonghua Gan Zang Bing Za Zhi 2022; 30:1218-1224. [PMID: 36891701 DOI: 10.3760/cma.j.cn501113-20220524-00278] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Subscribe] [Scholar Register] [Indexed: 03/10/2023]
Abstract
Objective: To investigate the efficacy and diagnostic accuracy of changes in cytokine levels before and after non-biological artificial liver (referred to as ABL) treatment in patients with acute-on-chronic liver failure (ACLF) in order to establish a basis for treatment timing selection and short-term (28d) prognosis. Methods: 90 cases diagnosed with ACLF were selected and divided into a group receiving artificial liver treatment (45 cases) and a group not receiving artificial liver treatment (45 cases). Age, gender, first routine blood test after admission, liver and kidney function, and procalcitonin (PCT) of the two groups were collected. The 28-day survival of the two groups was followed-up for survival analysis. The 45 cases who received artificial liver therapy were further divided into an improvement group and a deterioration group according to the clinical manifestations before discharge and the last laboratory examination results as the efficacy evaluation indicators. Routine blood test, coagulation function, liver and kidney function, PCT, alpha fetoprotein (AFP), β-defensin-1 (HBD-1), 12 cytokines and other indicators were analyzed and compared. A receiver operating characteristic curve (ROC curve) was used to analyze the diagnostic efficacy of the short-term (28 d) prognosis and an independent risk factors affecting the prognosis of ACLF patients. According to different data, Kaplan-Meier method, log-rant test, t-test, Mann-Whitney U test, Wilcoxon rank-sum test, χ2 test, Spearman rank correlation analysis and logistic regression analysis were used for statistical analysis. Results: The 28-day survival rate was significantly higher in ACLF patients who received artificial liver therapy than that of those who did not receive artificial liver therapy (82.2% vs. 61.0%, P<0.05). The levels of serum HBD-1, alpha interferon (IFN-α) and interleukin-5 (IL-5) after artificial liver treatment were significantly lower in ACLF patients than those before treatment (P<0.05), while liver and coagulation function were significantly improved compared with those before treatment (P<0.05), and there was no statistically significant difference in other serological indexes before and after treatment (P>0.05). Before artificial liver treatment, serum HBD-1 and INF-α levels were significantly lower in the ACLF improvement group than in the deterioration group (P<0.05) and were positively correlated with the patients' prognosis (deteriorating) (r=0.591, 0.427, P<0.001, 0.008). The level of AFP was significantly higher in the improved ACLF group than that in the deterioration group (P<0.05), and was negatively correlated with the prognosis (deteriorating) of the patients (r=-0.557, P<0.001). Univariate logistic regression analysis showed that HBD-1, IFN-α and AFP were independent risk factors for the prognosis of ACLF patients (P=0.001, 0.043, and 0.036, respectively), and that higher HBD-1 and IFN-α levels were associated with lower AFP level and a deteriorating prognosis. The area under the curve (AUC) of HBD-1, IFN-α, and AFP for short-term (28d) prognostic and diagnostic efficacy of ACLF patients was 0.883, 0.763, and 0.843, respectively, and the sensitivity and specificty was 0.75, 0.75, and 0.72, and 0.84, 0.80, and 0.83, respectively. The combination of HBD-1 and AFP had further improved the diagnostic efficiency of short-term prognosis of ACLF patients (AUC=0.960, sensitivity and specificity: 0.909 and 0.880 respectively). The combination of HBD-1+IFN-α+AFP had the highest diagnostic performance, with an AUC of 0.989, sensitivity of 0.900, and specificity of 0.947. Conclusion: Artificial liver therapy can effectively improve the clinical symptoms and liver and coagulation function of patients with ACLF; remove cytokines such as HBD-1, IFN-α, and IL-5 in patients with liver failure; delay or reverse the progression of the disease; and improve the survival rate of patients. HBD-1, IFN-α, and AFP are independent risk factors affecting the prognosis of ACLF patients, which can be used as biological indicators for evaluating the short-term prognosis of ACLF patients. The higher the level of HBD-1 and/or IFN-α, the higher the risk of disease deterioration. Therefore, artificial liver therapy should be started as soon as possible after the exclusion of infection. In diagnosing the prognosis of ACLF, HBD-1 has higher sensitivity and specificity than IFN-α and AFP, and its diagnostic efficiency is greatest when combined with IFN-α and AFP.
Collapse
Affiliation(s)
- X Y An
- Department of Traditional and Western Medical Hepatology, Third Hospital of Hebei Medical University, Shijiazhuang 050051, China
| | - L X Hu
- Department of Traditional and Western Medical Hepatology, Third Hospital of Hebei Medical University, Shijiazhuang 050051, China
| | - M Li
- Department of Traditional and Western Medical Hepatology, Third Hospital of Hebei Medical University, Shijiazhuang 050051, China
| | - B C Liu
- Department of Traditional and Western Medical Hepatology, Third Hospital of Hebei Medical University, Shijiazhuang 050051, China
| | - R Q Wang
- Department of Traditional and Western Medical Hepatology, Third Hospital of Hebei Medical University, Shijiazhuang 050051, China
| | - Y M Nan
- Department of Traditional and Western Medical Hepatology, Third Hospital of Hebei Medical University, Shijiazhuang 050051, China
| |
Collapse
|
11
|
Zhang XA, Tian F, Li Y, Zhang XL, Jiang BG, Liu BC, Zhang JT, Tian S, Ding H, Li S, Li H, Fang LQ, Liu W. Molecular detection and identification of relapsing fever Borrelia in ticks and wild small mammals in China. Emerg Microbes Infect 2022; 11:2632-2635. [PMID: 36214427 DOI: 10.1080/22221751.2022.2134054] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
Abstract
We identified relapsing fever (RF) Borrelia in 1.45% (145/10426) of the ticks and 1.40% (40/2850) of the wild mammals in a field investigation in China. Three RF Borrelia species, including human-pathogenic Borrelia miyamotoi, Borrelia persica and unclassified Babesia sp. were determined. Main species determined from ticks was B. miyamotoi (44.14%), followed by the unclassified Borrelia sp. (42.76%), and Borrelia theileri (13.10%). In wild mammals, main species found was B. persica (57.50%), followed by the unclassified Borrelia sp. (40.00%), and B. miyamotoi (2.50%). We determined B. theileri and B. persica in China for the first time. The coexistence of RF Borrelia species in one tick species in a given region was observed, with the most frequent coexistence seen for B. miyamotoi and the unclassified Borrelia sp. in Dermacentor silvarum, Haemaphysalis japonica, Haemaphysalis longicornis, and Ixodes persulcatuss respectively. The wide distribution and high variety of RF Borrelia in China pose a potential threat to public health.
Collapse
Affiliation(s)
- Xiao-Ai Zhang
- State Key Laboratory of Pathogen and Biosecurity, Beijing Institute of Microbiology and Epidemiology, Beijing 100071, P. R. China
| | - Feng Tian
- Urumqi Customs Port Outpatient Department, Xinjiang International Travel Health Care Center, Urumqi, 830011, P. R. China
| | - Yue Li
- State Key Laboratory of Pathogen and Biosecurity, Beijing Institute of Microbiology and Epidemiology, Beijing 100071, P. R. China
| | - Xiao-Long Zhang
- Science and Technology Research Center of China Customs (STRC), 100026, Beijing, P. R. China
| | - Bao-Gui Jiang
- State Key Laboratory of Pathogen and Biosecurity, Beijing Institute of Microbiology and Epidemiology, Beijing 100071, P. R. China
| | - Bao-Cheng Liu
- State Key Laboratory of Pathogen and Biosecurity, Beijing Institute of Microbiology and Epidemiology, Beijing 100071, P. R. China
| | - Jing-Tao Zhang
- State Key Laboratory of Pathogen and Biosecurity, Beijing Institute of Microbiology and Epidemiology, Beijing 100071, P. R. China
| | - Shen Tian
- School of Public Health, Guangzhou Medical University, Guangzhou, 511436, P. R. China
| | - Heng Ding
- State Key Laboratory of Pathogen and Biosecurity, Beijing Institute of Microbiology and Epidemiology, Beijing 100071, P. R. China
| | - Shuang Li
- State Key Laboratory of Pathogen and Biosecurity, Beijing Institute of Microbiology and Epidemiology, Beijing 100071, P. R. China
| | - Hao Li
- State Key Laboratory of Pathogen and Biosecurity, Beijing Institute of Microbiology and Epidemiology, Beijing 100071, P. R. China
| | - Li-Qun Fang
- State Key Laboratory of Pathogen and Biosecurity, Beijing Institute of Microbiology and Epidemiology, Beijing 100071, P. R. China
| | - Wei Liu
- State Key Laboratory of Pathogen and Biosecurity, Beijing Institute of Microbiology and Epidemiology, Beijing 100071, P. R. China.,School of Public Health, Peking University, Beijing, P. R. China
| |
Collapse
|
12
|
Tan YY, Yue SR, Lu AP, Zhang L, Ji G, Liu BC, Wang RR. The improvement of nonalcoholic steatohepatitis by Poria cocos polysaccharides associated with gut microbiota and NF-κB/CCL3/CCR1 axis. Phytomedicine 2022; 103:154208. [PMID: 35691078 DOI: 10.1016/j.phymed.2022.154208] [Citation(s) in RCA: 11] [Impact Index Per Article: 5.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 01/08/2022] [Revised: 05/18/2022] [Accepted: 05/24/2022] [Indexed: 06/15/2023]
Abstract
BACKGROUND Nonalcoholic steatohepatitis (NASH) has been linked to inflammation induced by intestinal microbiota. Poria cocos polysaccharides (PCP) possesses anti-inflammation and immunomodulation functions; however, its preventive effects against NASH and potential mechanisms need to be explored. METHODS The composition of PCP was determined using ion chromatography. C57BL/6 mice were administered the methionine and choline deficient (MCD) diet for 4 weeks to establish the NASH model or methionine-choline-sufficient (MCS) diet to serve as the control. Mice were assigned to the MCS group, MCD group, low-dose PCP (LP) group, and high-dose PCP (HP) group, and were administered the corresponding medications via gavage. Serum biochemical index analysis and liver histopathology examination were performed to verify the successful establishment of NASH model and to evaluate the efficacy of PCP. The composition of intestinal bacteria was profiled through 16S rRNA gene sequencing. Hepatic RNA sequencing (RNA-Seq) was performed to explore the potential mechanisms, which were further confirmed using qPCR, western blot, and immunohistochemistry. RESULTS PCP consists of glucose, galactose, mannose, D-glucosamine hydrochloride, xylose, arabinose, and fucose. PCP could significantly alleviate symptoms of NASH, including histological liver damage, impaired hepatic function, and increased oxidative stress. Meanwhile, HP could reshape the composition of intestinal bacteria by significantly increasing the relative abundance of Faecalibaculum and decreasing the level of endotoxin load derived from gut bacteria. PCP could also downregulate the expression of pathways associated with immunity and inflammation, including the chemokine signaling pathway, Toll-like receptor signaling pathway, and NF-kappa B signaling pathway. The expression levels of CCL3 and CCR1 (involved in the chemokine signaling pathway), Tlr4, Cd11b, and NF-κb (involved in the NF-kappa B signaling pathway), and Tnf-α (involved in the TNF signaling pathway) were significantly reduced in the HP group compared to the MCD group. CONCLUSIONS PCP could prevent the development of NASH, which may be associated with the modulation of intestinal microbiota and the downregulation of the NF-κB/CCL3/CCR1 axis.
Collapse
Affiliation(s)
- Yi-Yun Tan
- Shanghai Innovation Center of TCM Health Service, Shanghai University of Traditional Chinese Medicine, Shanghai 200032, China
| | - Si-Ran Yue
- Shanghai Innovation Center of TCM Health Service, Shanghai University of Traditional Chinese Medicine, Shanghai 200032, China
| | - Ai-Ping Lu
- Shanghai Innovation Center of TCM Health Service, Shanghai University of Traditional Chinese Medicine, Shanghai 200032, China; School of Chinese Medicine, Hong Kong Baptist University, Kowloon Tong, Hong Kong, China
| | - Lei Zhang
- Shanghai Innovation Center of TCM Health Service, Shanghai University of Traditional Chinese Medicine, Shanghai 200032, China
| | - Guang Ji
- Shanghai Innovation Center of TCM Health Service, Shanghai University of Traditional Chinese Medicine, Shanghai 200032, China; Institute of Digestive Diseases, Longhua Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai 200032, China.
| | - Bao-Cheng Liu
- Shanghai Innovation Center of TCM Health Service, Shanghai University of Traditional Chinese Medicine, Shanghai 200032, China.
| | - Rui-Rui Wang
- Shanghai Innovation Center of TCM Health Service, Shanghai University of Traditional Chinese Medicine, Shanghai 200032, China.
| |
Collapse
|
13
|
Cook NE, Kissinger-Knox A, Iverson IA, Liu BC, Iverson GL. A-11 Social Determinants of Health in the Diagnosis and Management of Pediatric Concussion: A Content Analysis. Arch Clin Neuropsychol 2022. [DOI: 10.1093/arclin/acac32.11] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
Abstract
Purpose: This content analysis examined the literature underlying the Centers for Disease Control and Prevention Guideline on the Diagnosis and Management of Mild Traumatic Brain Injury Among Children (i.e., the “Guideline”) to determine the extent to which social determinants of health (SDH) were examined or addressed. Methods: A published systematic review, that formed the basis for the Guideline, included 37 studies addressing diagnosis, prognosis, and treatment/rehabilitation. We examined those studies to identify SDH domains and associated subcategories derived from the Healthy People 2020 and 2030 websites. Pairs of raters coded each article with disagreements resolved by consensus. Results: At least one SDH domain was represented in 60% of the articles, usually mentioned descriptively, as a covariate, or as a design consideration. Very few were addressed as a primary focus of the study. The most frequently represented SDH domain was Education Access (43.2% of studies), receiving credit most often for reporting on participants with learning disabilities. Social and Community Context, broadly defined, was represented in nearly 1 of 3 studies (29.7%). Economic Stability and Health Care Access domains were included in 6 studies (16.2%). Some studies (k = 6, 16.2%) referenced SDH as important to consider for future research. The Guideline includes some commentary on health literacy and socioeconomic status. Conclusions: Social determinants of health are largely unrepresented as important or meaningful variables influencing the Guideline on the Diagnosis and Management of Mild Traumatic Brain Injury Among Children, or in the studies included in the systematic review that informed the guideline.
Collapse
|
14
|
Liu BC, Gaudet CE, Schatz P, Berkner P, Iverson GL. A-26 The Prevalence of Invalid Baseline ImPACT® Test Scores in Adolescent Student Athletes. Arch Clin Neuropsychol 2022. [DOI: 10.1093/arclin/acac32.26] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
Abstract
Purpose: Immediate Post-Concussion and Cognitive Testing (ImPACT®) is among the most commonly used neuropsychological measures to establish a baseline estimate of neuropsychological functioning for concussion management. We sought to identify correlates of invalid performance on ImPACT® baseline testing in adolescents. Methods: The sample included 67,009 English-speaking adolescents (ages 14–18, mean: 15.51, SD: 1.22) who completed ImPACT® baseline tests in English between 2009 and 2019. The association between invalid performance (as determined by the embedded invalidity indicators) and demographic and health variables was assessed using chi-square tests and with odds ratios (OR). Results: Overall, 7.2% of adolescents produced invalid baseline tests. Boys (7.9%) produced more invalid baselines than girls (6.2%; χ2 = 70.35, p < 0.001, OR = 1.29, 95% CI = 1.22, 1.37). Adolescents with learning disabilities (16.4%), attention-deficit/hyperactivity disorder (11.1%), and those who have received special education services (16.0%) or repeated more than 1 year of school (11.0%), all obtained invalid baselines at higher frequencies than those who did not endorse these variables (i.e., 6.5%–6.8%; p < 0.001). Adolescents who reported receiving treatment for headaches (9.5%), migraines (9.4%), epilepsy/seizures (11.1%), substance/alcohol use (17.0%), or a psychiatric condition (10.0%) obtained invalid baselines at higher frequencies than those who did not (i.e., 6.6%–6.9%; p < 0.001). Conclusions: Consistent with prior research, approximately 7% of adolescents produced invalid baselines. However, the frequencies of invalid performances were substantially greater for subgroups such as those with learning disabilities, those who have received special education services, and youth who have received past substance abuse treatment.
Collapse
|
15
|
Che TL, Li XL, Tian JB, Wang G, Peng XF, Zhang HY, Chen JH, Zhu Y, Zhang WH, Wang T, Liu BC, Xu Q, Lv CL, Jiang BG, Li ZJ, Fang LQ, Liu W. The role of selenium in severe fever with thrombocytopenia syndrome: an integrative analysis of surveillance data and clinical data. Int J Infect Dis 2022; 122:38-45. [PMID: 35605950 DOI: 10.1016/j.ijid.2022.05.042] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/08/2022] [Revised: 05/15/2022] [Accepted: 05/17/2022] [Indexed: 11/17/2022] Open
Abstract
OBJECTIVES Selenium deficiency can be associated with increased susceptibility to some viral infections and even more severe diseases. In this study, we aimed to examine whether this association applies to severe fever with thrombocytopenia syndrome (SFTS). METHOD An observational study was conducted based on the data of 13,305 human SFTS cases reported in mainland China from 2010 to 2020. The associations among incidence, case fatality rate of SFTS, and crop selenium concentration at the county level were explored. The selenium level in a cohort of patients with SFTS was tested, and its relationship with clinical outcomes was evaluated. RESULTS The association between selenium-deficient crops and the incidence rate of SFTS was confirmed by multivariate Poisson analysis, with an estimated incidence rate ratio (IRR, 95% confidence interval [CI]) of 4.549 (4.215-4.916) for moderate selenium-deficient counties and 16.002 (14.706-17.431) for severe selenium-deficient counties. In addition, a higher mortality rate was also observed in severe selenium-deficient counties with an IRR of 1.409 (95% CI: 1.061-1.909). A clinical study on 120 patients with SFTS showed an association between serum selenium deficiency and severe SFTS (odds ratio, OR: 2.94; 95% CI: 1.00-8.67) or fatal SFTS (OR: 7.55; 95% CI: 1.14-50.16). CONCLUSION Selenium deficiency is associated with increased susceptibility to SFTS and poor clinical outcomes.
Collapse
Affiliation(s)
- Tian-Le Che
- State Key Laboratory of Pathogen and Biosecurity, Beijing Institute of Microbiology and Epidemiology, Beijing, P. R. China
| | - Xin-Lou Li
- Department of Medical Research, Key Laboratory of Environmental Sense Organ Stress and Health of the Ministry of Environmental Protection, PLA Strategic Support Force Medical Center, Beijing, P. R. China
| | - Jian-Bo Tian
- Department of Epidemiology and Biostatistics, School of Public Health, Wuhan University, Wuhan, 430000, China
| | - Gang Wang
- State Key Laboratory of Pathogen and Biosecurity, Beijing Institute of Microbiology and Epidemiology, Beijing, P. R. China
| | - Xue-Fang Peng
- State Key Laboratory of Pathogen and Biosecurity, Beijing Institute of Microbiology and Epidemiology, Beijing, P. R. China
| | - Hai-Yang Zhang
- Center for Disease Control and Prevention of Central Theater Command, Beijing, P. R. China
| | - Jia-Hao Chen
- State Key Laboratory of Pathogen and Biosecurity, Beijing Institute of Microbiology and Epidemiology, Beijing, P. R. China
| | - Ying Zhu
- Department of Epidemiology and Biostatistics, School of Public Health, Wuhan University, Wuhan, 430000, China
| | - Wen-Hui Zhang
- Health Supervision Institute of Dongcheng District, Beijing, P. R. China
| | - Tao Wang
- State Key Laboratory of Pathogen and Biosecurity, Beijing Institute of Microbiology and Epidemiology, Beijing, P. R. China
| | - Bao-Cheng Liu
- State Key Laboratory of Pathogen and Biosecurity, Beijing Institute of Microbiology and Epidemiology, Beijing, P. R. China
| | - Qiang Xu
- State Key Laboratory of Pathogen and Biosecurity, Beijing Institute of Microbiology and Epidemiology, Beijing, P. R. China
| | - Chen-Long Lv
- State Key Laboratory of Pathogen and Biosecurity, Beijing Institute of Microbiology and Epidemiology, Beijing, P. R. China
| | - Bao-Gui Jiang
- State Key Laboratory of Pathogen and Biosecurity, Beijing Institute of Microbiology and Epidemiology, Beijing, P. R. China
| | - Zhong-Jie Li
- Division of Infectious Disease, Key Laboratory of Surveillance and Early-Warning on Infectious Disease, Chinese Center for Disease Control and Prevention, Beijing, P. R. China.
| | - Li-Qun Fang
- State Key Laboratory of Pathogen and Biosecurity, Beijing Institute of Microbiology and Epidemiology, Beijing, P. R. China.
| | - Wei Liu
- State Key Laboratory of Pathogen and Biosecurity, Beijing Institute of Microbiology and Epidemiology, Beijing, P. R. China; Beijing Key Laboratory of Vector Borne and Natural Focus Infectious Diseases, Beijing 100071, P. R. China; Graduate School of Anhui Medical University, Hefei 230601, P.R. China.
| |
Collapse
|
16
|
Yang MZ, Li L, Wei H, Liu BC, Liu KQ, Li DP, Zhang L, Yang RC, Mi YC, Wang JX, Wang Y. [Clinical and genetic characteristics of patients with newly diagnosed acute promyelocytic leukemia: a single-center retrospective of 790 cases]. Zhonghua Xue Ye Xue Za Zhi 2022; 43:336-341. [PMID: 35680634 PMCID: PMC9189486 DOI: 10.3760/cma.j.issn.0253-2727.2022.04.012] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 11/14/2021] [Indexed: 11/05/2022]
Abstract
Objective: To retrospectively analyze the data of Chinese patients with newly diagnosed acute promyelocytic leukemia (APL) to preliminarily discuss the clinical and cytogenetic characteristics. Methods: From February 2004 to June 2020, patients with newly diagnosed APL aged ≥ 15 years who were admitted to the Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Science & Peking Union Medical College were chosen. Clinical and laboratory features were retrospectively analyzed. Results: A total of 790 cases were included, with a male to female ratio of 1.22. The median age of the patients was 41 (15-76) years. Patients aged between 20 and 59 predominated, with 632 patients (80%) of 790 patients classified as low and intermediate risk and 158 patients (20%) of 790 patients classified as high risk. The white blood cell, platelet, and hemoglobin levels at diagnosis were 2.3 (0.1-176.1) ×10(9)/L, 29.5 (2.0-1220.8) ×10(9)/L, and 89 (15-169) g/L, respectively, and 4.8% of patients were complicated with psoriasis. The long-form type of PML-RARα was most commonly seen in APL, accounting for 58%. Both APTT extension (10.3%) and creatinine>14 mg/L (1%) are rarely seen in patients at diagnosis. Cytogenetics was performed in 715 patients with newly diagnosed APL. t (15;17) with additional chromosomal abnormalities were found in 155 patients, accounting for 21.7%; among which, +8 was most frequently seen. A complex karyotype was found in 64 (9.0%) patients. Next-generation sequencing was performed in 178 patients, and 113 mutated genes were discovered; 75 genes had an incidence rate>1%. FLT3 was the most frequently seen, which accounted for 44.9%, and 20.8% of the 178 patients present with FLT3-ITD. Conclusions: Patients aged 20-59 years are the most common group with newly diagnosed APL. No obvious difference was found in the ratio of males to females. In terms of risk stratification, patients divided into low and intermediate risk predominate. t (15;17) with additional chromosomal abnormalities accounted for 21% of 715 patients, in which +8 was most commonly seen. The long-form subtype was most frequently seen in PML-RARα-positive patients, and FLT3 was most commonly seen in the mutation spectrum of APL.
Collapse
Affiliation(s)
- M Z Yang
- State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin 300020, China
| | - L Li
- State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin 300020, China
| | - H Wei
- State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin 300020, China
| | - B C Liu
- State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin 300020, China
| | - K Q Liu
- State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin 300020, China
| | - D P Li
- State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin 300020, China
| | - L Zhang
- State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin 300020, China
| | - R C Yang
- State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin 300020, China
| | - Y C Mi
- State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin 300020, China
| | - J X Wang
- State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin 300020, China
| | - Y Wang
- State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin 300020, China
| |
Collapse
|
17
|
Yue SR, Tan YY, Zhang L, Zhang BJ, Jiang FY, Ji G, Liu BC, Wang RR. Gynostemma pentaphyllum polysaccharides ameliorate non-alcoholic steatohepatitis in mice associated with gut microbiota and the TLR2/NLRP3 pathway. Front Endocrinol (Lausanne) 2022; 13:885039. [PMID: 35937847 PMCID: PMC9352886 DOI: 10.3389/fendo.2022.885039] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 02/27/2022] [Accepted: 06/28/2022] [Indexed: 12/24/2022] Open
Abstract
Recent studies have revealed the pivotal role of gut microbiota in the progress of liver diseases including non-alcoholic steatohepatitis (NASH). Many natural herbs, such as Gynostemma pentaphyllum (GP), have been extensively applied in the prevention of NASH, while the bioactive components and underlying mechanism remain unclear. The aim of this study was to investigate whether the polysaccharides of GP (GPP) have a protective effect on NASH and to explore the potential mechanism underlying these effects. C57BL/6 male mice were fed with a methionine-choline-deficient (MCD) diet for 4 weeks to induce NASH and administered daily oral gavage of sodium carboxymethylcellulose (CMC-Na), low dose of GPP (LGPP), high dose of GPP (HGPP), and polyene phosphatidylcholine capsules (PPC), compared with the methionine-choline-sufficient (MCS) group. Our results showed that the symptoms of hepatic steatosis, hepatocyte ballooning, liver fibrosis, and oxidative stress could be partially recovered through the intervention of GPP with a dose-dependent effect. Furthermore, gut microbiome sequencing revealed that HGPP altered the composition of gut microbiota, mainly characterized by the enrichment of genera including Akkermansia, Lactobacillus, and A2. Moreover, hepatic transcriptome analysis indicated that the anti-inflammatory effect of HGPP might be associated with toll-like receptor (TLR) and nod-like receptor (NLR) signaling pathways. HGPP could inhibit the expression of TLR2 and downregulate the expression of the NLRP3 inflammasome, as well as the pro-inflammatory cytokine tumor necrosis factor (TNF)-α and interleukin (IL)-1β. In summary, GPP could ameliorate NASH possibly mediated via the modulation of gut microbiota and the TLR2/NLRP3 signaling pathway, indicating that GPP could be tested as a prebiotic agent in the prevention of NASH.
Collapse
Affiliation(s)
- Si-Ran Yue
- Shanghai Innovation Center of Traditional Chinese Medicine Health Service, Shanghai University of Traditional Chinese Medicine, Shanghai, China
| | - Yi-Yun Tan
- Shanghai Innovation Center of Traditional Chinese Medicine Health Service, Shanghai University of Traditional Chinese Medicine, Shanghai, China
| | - Lei Zhang
- Shanghai Innovation Center of Traditional Chinese Medicine Health Service, Shanghai University of Traditional Chinese Medicine, Shanghai, China
| | - Bao-Jun Zhang
- Shanghai Innovation Center of Traditional Chinese Medicine Health Service, Shanghai University of Traditional Chinese Medicine, Shanghai, China
| | - Feng-Yan Jiang
- Shanghai Innovation Center of Traditional Chinese Medicine Health Service, Shanghai University of Traditional Chinese Medicine, Shanghai, China
| | - Guang Ji
- Shanghai Innovation Center of Traditional Chinese Medicine Health Service, Shanghai University of Traditional Chinese Medicine, Shanghai, China
- Institute of Digestive Diseases, Longhua Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai, China
- *Correspondence: Rui-Rui Wang, ; Bao-Cheng Liu, ; Guang Ji,
| | - Bao-Cheng Liu
- Shanghai Innovation Center of Traditional Chinese Medicine Health Service, Shanghai University of Traditional Chinese Medicine, Shanghai, China
- *Correspondence: Rui-Rui Wang, ; Bao-Cheng Liu, ; Guang Ji,
| | - Rui-Rui Wang
- Shanghai Innovation Center of Traditional Chinese Medicine Health Service, Shanghai University of Traditional Chinese Medicine, Shanghai, China
- *Correspondence: Rui-Rui Wang, ; Bao-Cheng Liu, ; Guang Ji,
| |
Collapse
|
18
|
Zhao TS, Zeng HL, Zhang X, Chen X, Jiang WL, Du J, Liu HY, Zhao J, Yuan Y, Peng XF, Li JC, Yang T, Liu BC, Li HJ, Zhang XA, Fang LQ, Lu QB, Cui F, Liu W. Neurological manifestations in COVID-19 patients and their application in predicting fatal disease: A retrospective cohort study. J Microbiol Immunol Infect 2021; 55:445-453. [PMID: 34503922 PMCID: PMC8384758 DOI: 10.1016/j.jmii.2021.07.010] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 01/28/2021] [Revised: 07/11/2021] [Accepted: 07/19/2021] [Indexed: 01/06/2023]
Abstract
Background To explore the development of central nervous system (CNS) symptoms and clinical application in predicting the clinical outcomes of SARS-COV-2 patients. Methods A retrospective cohort study was performed on the hospitalized patients with SARS-COV-2 recruited from four hospitals in Hubei Province, China from 18 January to 10 March 2020. The patients with CNS symptoms were determined. Data regarding clinical symptoms and laboratory tests were collected from medical records. Results Of 1268 patients studied, 162 (12.8%) had CNS symptoms, manifested as unconsciousness (71, 5.6%), coma (69, 5.4%), dysphoria (50, 3.9%), somnolence (34, 2.7%) and convulsion (3, 0.2%), which were observed at median of 14 (interquartile range 9–18) days after symptom onset and significantly associated with older age (OR = 5.71, 95% confidence interval [CI] 2.78–11.73), male (OR = 1.73, 95% CI 1.22–2.47) and preexisting hypertension (OR = 1.78, 95% CI 1.23–2.57). The presence of CNS symptoms could be predicted by abnormal laboratory tests across various clinical stages, including by lymphocyte counts of <0.93 × 109/L, LDH≥435 U/L and IL-6≥28.83 pg/L at 0–10 days post disease; by lymphocyte count<0.86 × 109/L, IL-2R ≥ 949 U/L, LDH≥382 U/L and WBC≥8.06 × 109/L at 11–20 days post disease. More patients with CNS symptoms developed fatal outcome compared with patients without CNS symptoms (HR = 33.96, 95% CI 20.87–55.16). Conclusion Neurological symptoms of COVID-19 were related to increased odds of developing poor prognosis and even fatal infection.
Collapse
Affiliation(s)
- Tian-Shuo Zhao
- Department of Laboratorial Science and Technology & Vaccine Research Center, School of Public Health, Peking University, Beijing, 100191, PR China
| | - Hao-Long Zeng
- Department of Laboratory Medicine, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430030, PR China
| | - Xin Zhang
- Huangmei People's Hospital, Huanggang, 436500, PR China
| | - Xi Chen
- Department of Thoracic and Vascular Surgery, Wuhan No. 1 Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430022, PR China
| | - Wan-Li Jiang
- Department of Thoracic Surgery, Renmin Hospital of Wuhan University, Wuhan, 430060, PR China
| | - Juan Du
- Department of Laboratorial Science and Technology & Vaccine Research Center, School of Public Health, Peking University, Beijing, 100191, PR China
| | - Han-Yu Liu
- Department of Laboratorial Science and Technology & Vaccine Research Center, School of Public Health, Peking University, Beijing, 100191, PR China
| | - Jing Zhao
- State Key Laboratory of Pathogen and Biosecurity, Beijing Institute of Microbiology and Epidemiology, Beijing, 100071, PR China
| | - Yang Yuan
- State Key Laboratory of Pathogen and Biosecurity, Beijing Institute of Microbiology and Epidemiology, Beijing, 100071, PR China
| | - Xue-Fang Peng
- State Key Laboratory of Pathogen and Biosecurity, Beijing Institute of Microbiology and Epidemiology, Beijing, 100071, PR China
| | - Jia-Chen Li
- State Key Laboratory of Pathogen and Biosecurity, Beijing Institute of Microbiology and Epidemiology, Beijing, 100071, PR China
| | - Tong Yang
- State Key Laboratory of Pathogen and Biosecurity, Beijing Institute of Microbiology and Epidemiology, Beijing, 100071, PR China
| | - Bao-Cheng Liu
- State Key Laboratory of Pathogen and Biosecurity, Beijing Institute of Microbiology and Epidemiology, Beijing, 100071, PR China
| | - Hui-Jun Li
- Department of Laboratory Medicine, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430030, PR China
| | - Xiao-Ai Zhang
- State Key Laboratory of Pathogen and Biosecurity, Beijing Institute of Microbiology and Epidemiology, Beijing, 100071, PR China
| | - Li-Qun Fang
- State Key Laboratory of Pathogen and Biosecurity, Beijing Institute of Microbiology and Epidemiology, Beijing, 100071, PR China
| | - Qing-Bin Lu
- Department of Laboratorial Science and Technology & Vaccine Research Center, School of Public Health, Peking University, Beijing, 100191, PR China.
| | - Fuqiang Cui
- Department of Laboratorial Science and Technology & Vaccine Research Center, School of Public Health, Peking University, Beijing, 100191, PR China.
| | - Wei Liu
- Department of Laboratorial Science and Technology & Vaccine Research Center, School of Public Health, Peking University, Beijing, 100191, PR China; State Key Laboratory of Pathogen and Biosecurity, Beijing Institute of Microbiology and Epidemiology, Beijing, 100071, PR China.
| |
Collapse
|
19
|
Wang HF, Zhang YL, Liu XL, Zhu HL, Liang R, Liu BC, Zhou L, Meng L, Li WM, Jiang Q. [Treatment status of tyrosine kinase inhibitors in Chinese patients with chronic myeloid leukemia in 2020]. Zhonghua Xue Ye Xue Za Zhi 2021; 42:535-542. [PMID: 34455739 PMCID: PMC8408488 DOI: 10.3760/cma.j.issn.0253-2727.2021.07.002] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Indexed: 02/05/2023]
Abstract
目的 调查中国慢性髓性白血病(CML)患者的治疗现状。 方法 横断面研究,2020年4月末至5月中旬,以填写调研问卷的形式在全国范围内调研CML患者,分析酪氨酸激酶抑制剂(TKI)一线选择、目前用药、药物转换和获得主要分子学反应(MMR)的比例及其影响因素。 结果 2933份来自全国31个省市自治区CML受访者的问卷可供分析,男性1683例(57.4%),中位年龄38(16~87)岁。一线选择:伊马替尼2481例(84.6%),原创性新药(原研药)1803例(61.5%)。填写问卷时用药:伊马替尼1765例(60.2%),原研药1791例(61.1%)。共1185例(40.4%)受访者曾经历TKI药物转换。1944例初发慢性期受访者TKI中位治疗45(3~227)个月,1417例(72.9%)获得≥MMR的疗效。多因素分析显示,城镇户籍(OR=0.6,95%CI 0.5~0.8,P<0.001)、≥大学学历(OR=0.5,95%CI 0.4~0.7,P<0.001)和进展期(OR=0.5,95%CI 0.3~0.8,P=0.001)受访者更少首选仿制TKI,而来自中部地区受访者比东部地区更多首选国产仿制TKI(OR=1.7,95%CI 1.4~2.0,P<0.001)。进展期受访者更多首选二代TKI(OR=5.4,95%CI 3.6~8.2,P<0.001),≥60岁受访者更少首选二代TKI(OR=0.4,95%CI 0.2~0.7,P=0.002)。诊断时处于进展期(OR=2.2,95%CI 1.6~3.2,P<0.001)、首选伊马替尼(OR=2.0,95%CI 1.6~2.6,P<0.001)、首选国产仿制药(OR=1.3,95%CI 1.1~1.6,P=0.002)、诊断距开始TKI治疗的时间更长(OR=1.2,95%CI 1.1~1.2,P<0.001)和服用TKI的时间更长(OR=1.1,95%CI 1.0~1.1,P<0.001)与药物转换比例增高显著相关。城镇户籍(OR=0.7,95%CI 0.6~0.8,P<0.001)、获≥MMR(OR=0.6,95%CI 0.5~0.8,P<0.001)和疗效未知(OR=0.7,95%CI 0.6~0.9,P=0.003)与药物转换比例低显著相关。女性(OR=1.4,95%CI 1.1~1.7,P=0.003)、城镇户籍(OR=1.6,95%CI 1.3~2.0,P<0.001)、初始服用伊马替尼(OR=1.4,95%CI 1.1~1.9,P=0.016)和TKI治疗时间更长(OR=1.2,95%CI 1.2~1.3,P<0.001)与获得≥MMR显著相关,而年龄≥60岁(OR=0.7,95%CI 0.4~1.0,P=0.047)和药物转换(OR=0.6,95%CI 0.5~0.7,P<0.001)与未获得MMR显著相关。 结论 截至2020年,中国CML患者中大多数首选并持续服用伊马替尼,半数以上服用原研药。社会人口学特征和疾病分期影响了患者的TKI选择、药物转换和治疗反应。
Collapse
Affiliation(s)
- H F Wang
- Peking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing 100044, China
| | - Y L Zhang
- Department of Hematology, Affiliated Cancer Hospital of Zhengzhou University, Henan Provincial Tumor Hospital, Zhengzhou 450008, China
| | - X L Liu
- Department of Hematology, Nanfang Hospital, Southern Medical University, Guangzhou 510515, China
| | - H L Zhu
- Department of Hematology, West China Hospital, Sichuan University, Chengdu 610041, China
| | - R Liang
- Department of Hematology, Xijing Hospital, Air Force Medical University, Xi'an 510370, China
| | - B C Liu
- Institute of Hematology, Chinese Academy of Medical Science, Tianjin 300020, China
| | - L Zhou
- Shanghai Institute of Hematology, State Key Laboratory of Medical Genomics, National Research Center for Translational Medicine at Shanghai, Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai 200025, China
| | - L Meng
- Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China
| | - W M Li
- Department of Hematology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, China
| | - Q Jiang
- Peking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing 100044, China
| |
Collapse
|
20
|
Zhang GJ, Gong XY, Qiu SW, Zhou CL, Liu KQ, Lin D, Liu BC, Wei H, Wei SN, Li Y, Gu RX, Gong BF, Liu YT, Fang QY, Mi YC, Wang Y, Wang JX. [Dasatinib combined with multi-agent chemotherapy regimen in newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia: a prospective study from a single center]. Zhonghua Xue Ye Xue Za Zhi 2021; 42:109-115. [PMID: 33858040 PMCID: PMC8071668 DOI: 10.3760/cma.j.issn.0253-2727.2021.02.004] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Abstract
目的 评价达沙替尼联合多药化疗方案在Ph染色体阳性急性淋巴细胞白血病(Ph+ ALL)患者中的疗效及安全性。 方法 前瞻性、单臂、开放的临床研究。2016年1月至2018年4月中国医学科学院血液病医院收治的30例初诊成人Ph+ ALL患者入组。采用多药化疗方案,标准诱导化疗为期4周,自诱导化疗第8天开始口服达沙替尼(商品名依尼舒,正大天晴药业集团股份有限公司产品)100 mg/d,持续应用至整体治疗结束。有条件和意愿进行移植者,可进行异基因造血干细胞移植或自体造血干细胞移植。 结果 所有30例患者在诱导治疗4周后均达到血液学完全缓解(HCR),累积完全分子学反应(MCR)率为70.0%(21/30)。中位随访时间为37.8(32.0~46.6)个月。3年总生存(OS)率为68.1%,3年无血液学复发生存(HRFS)率为61.6%。63.3%的患者在治疗3个月时达到主要分子学反应(MMR)(其中有43.3%患者达到MCR)。6个月时60.0%的患者达到MCR,达到MCR的患者具有更好的OS(P=0.004)、HRFS(P=0.049)和EFS(P=0.001)。15例(50.0%)患者在第1次HCR期内进行移植,移植组患者HRFS(P=0.030)和EFS(P=0.010)优于化疗组。 结论 达沙替尼联合多药化疗方案治疗初诊Ph+ALL安全有效。 临床试验注册 ClinicalTrials.gov,NCT02523976。
Collapse
Affiliation(s)
- G J Zhang
- State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin 300020, China
| | - X Y Gong
- State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin 300020, China
| | - S W Qiu
- State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin 300020, China
| | - C L Zhou
- State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin 300020, China
| | - K Q Liu
- State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin 300020, China
| | - D Lin
- State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin 300020, China
| | - B C Liu
- State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin 300020, China
| | - H Wei
- State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin 300020, China
| | - S N Wei
- State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin 300020, China
| | - Y Li
- State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin 300020, China
| | - R X Gu
- State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin 300020, China
| | - B F Gong
- State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin 300020, China
| | - Y T Liu
- State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin 300020, China
| | - Q Y Fang
- State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin 300020, China
| | - Y C Mi
- State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin 300020, China
| | - Y Wang
- State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin 300020, China
| | - J X Wang
- State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin 300020, China
| |
Collapse
|
21
|
Mei CL, Chen XN, Hao CM, Hu Z, Jiang HL, Li GS, Liu BC, Liu H, Liu ZS, Xing CY, Yao L, Yu C, Yuan WJ, Zuo L. [Development of a hyperkalemia risk assessment model for patients with chronic kidney disease]. Zhonghua Yi Xue Za Zhi 2020; 100:3498-3503. [PMID: 33256291 DOI: 10.3760/cma.j.cn112137-20200904-02561] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/12/2023]
Abstract
Objective: To investigate risk factors for hyperkalemia among chronic kidney disease (CKD) patients and establish a risk assessment model for predicting hyperkalemia events. Methods: Clinical data of CKD patients (stage 3 to 5) hospitalized between May 2017 and June 2020 from 14 hospitals were retrospectively collected and divided into training dataset and validation dataset through balanced random sampling. Multivariate logistic regression analysis was used to analyze risk factors for hyperkalemia in CKD patients and the factors were scored. Receiver operating characteristic (ROC) curve was plotted and the area under the curve (AUC) was calculated. Meanwhile, the cut-off value with the best sensitivity and specificity were used to verify the accuracy of the model in validation dataset. Results: A total of 847 CKD patients were enrolled and further divided into training dataset (n=675) and validation dataset (n=172). There were 555 males and 292 females, with a mean age of (57.2±15.6) years. Multivariate logistic regression analysis showed that age, CKD stage, history of heart failure, history of serum potassium ≥5.0 mmol/L, diabetes, metabolic acidosis, and use of medications that increase serum potassium levels were risk factors for causing hyperkalemia in patients with CKD. Risk assessment model was established based on these risk factors. The AUC of the ROC curve was 0.809. Using 4 as the cut-off value, the sensitivity and specificity for predicting hyperkalemia events reached 87.1% and 57.0%, respectively. Conclusion: The model established in the current study can be used for predicting hyperkalemia events in clinical practices, which offers a new way to optimize serum potassium management in patients with CKD.
Collapse
Affiliation(s)
- C L Mei
- Department of Nephrology, Changzheng Hospital, Shanghai 200003, China
| | - X N Chen
- Department of Nephrology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200025, China
| | - C M Hao
- Department of Nephrology, Huashan Hospital Affiliated to Fudan University, Shanghai 200041, China
| | - Z Hu
- Department of Nephrology, Qilu Hospital, Shandong University, Jinan 250012, China
| | - H L Jiang
- Department of Blood Purification, the First Affiliated Hospital of Xi'an Jiao Tong University, Xi'an 710061, China
| | - G S Li
- Department of Nephrology, Sichuan Provincial People's Hospital, Chengdu 610072, China
| | - B C Liu
- Department of Nephrology, Zhongda Hospital Affiliated to Southeast University, Nanjing 210009, China
| | - H Liu
- Department of Nephrology, the Second Xiangya Hospital of Central South University, Changsha 410001, China
| | - Z S Liu
- Department of Nephropathy Rheumatology, the First Affiliated Hospital of Zhengzhou University, Zhengzhou 450052, China
| | - C Y Xing
- Department of Nephrology, Jiangsu Provincial People's Hospital, Nanjing 210029, China
| | - L Yao
- Department of Nephrology, the First Affiliated Hospital of China Medical University, Shenyang 110001, China
| | - C Yu
- Department of Nephrology, Tongji Hospital, Tongji University, Shanghai 200065, China
| | - W J Yuan
- Department of Nephrology, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200080, China
| | - L Zuo
- Department of Nephrology, Peking University People's Hospital, Beijing 100044, China
| |
Collapse
|
22
|
Lu QB, Zhang Y, Liu MJ, Zhang HY, Jalali N, Zhang AR, Li JC, Zhao H, Song QQ, Zhao TS, Zhao J, Liu HY, Du J, Teng AY, Zhou ZW, Zhou SX, Che TL, Wang T, Yang T, Guan XG, Peng XF, Wang YN, Zhang YY, Lv SM, Liu BC, Shi WQ, Zhang XA, Duan XG, Liu W, Yang Y, Fang LQ. Epidemiological parameters of COVID-19 and its implication for infectivity among patients in China, 1 January to 11 February 2020. Euro Surveill 2020; 25:2000250. [PMID: 33034281 PMCID: PMC7545819 DOI: 10.2807/1560-7917.es.2020.25.40.2000250] [Citation(s) in RCA: 18] [Impact Index Per Article: 4.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/06/2020] [Accepted: 07/14/2020] [Indexed: 01/08/2023] Open
Abstract
BackgroundThe natural history of disease in patients infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) remained obscure during the early pandemic.AimOur objective was to estimate epidemiological parameters of coronavirus disease (COVID-19) and assess the relative infectivity of the incubation period.MethodsWe estimated the distributions of four epidemiological parameters of SARS-CoV-2 transmission using a large database of COVID-19 cases and potential transmission pairs of cases, and assessed their heterogeneity by demographics, epidemic phase and geographical region. We further calculated the time of peak infectivity and quantified the proportion of secondary infections during the incubation period.ResultsThe median incubation period was 7.2 (95% confidence interval (CI): 6.9‒7.5) days. The median serial and generation intervals were similar, 4.7 (95% CI: 4.2‒5.3) and 4.6 (95% CI: 4.2‒5.1) days, respectively. Paediatric cases < 18 years had a longer incubation period than adult age groups (p = 0.007). The median incubation period increased from 4.4 days before 25 January to 11.5 days after 31 January (p < 0.001), whereas the median serial (generation) interval contracted from 5.9 (4.8) days before 25 January to 3.4 (3.7) days after. The median time from symptom onset to discharge was also shortened from 18.3 before 22 January to 14.1 days after. Peak infectivity occurred 1 day before symptom onset on average, and the incubation period accounted for 70% of transmission.ConclusionThe high infectivity during the incubation period led to short generation and serial intervals, necessitating aggressive control measures such as early case finding and quarantine of close contacts.
Collapse
Affiliation(s)
- Qing-Bin Lu
- Department of Laboratorial Science and Technology, School of Public Health, Peking University, Beijing, China
- These authors contributed equally to this manuscript
| | - Yong Zhang
- These authors contributed equally to this manuscript
- School of Mathematical Sciences, Beijing Normal University, Beijing, China
| | - Ming-Jin Liu
- Department of Biostatistics, College of Public Health and Health Professions, and Emerging Pathogens Institute, University of Florida, Gainesville, United States
| | - Hai-Yang Zhang
- State Key Laboratory of Pathogen and Biosecurity, Beijing Institute of Microbiology and Epidemiology, Beijing, China
| | - Neda Jalali
- Department of Biostatistics, College of Public Health and Health Professions, and Emerging Pathogens Institute, University of Florida, Gainesville, United States
| | - An-Ran Zhang
- Department of Biostatistics, College of Public Health and Health Professions, and Emerging Pathogens Institute, University of Florida, Gainesville, United States
- State Key Laboratory of Pathogen and Biosecurity, Beijing Institute of Microbiology and Epidemiology, Beijing, China
| | - Jia-Chen Li
- State Key Laboratory of Pathogen and Biosecurity, Beijing Institute of Microbiology and Epidemiology, Beijing, China
| | - Han Zhao
- School of Mathematical Sciences, Beijing Normal University, Beijing, China
| | - Qian-Qian Song
- School of Mathematical Sciences, Beijing Normal University, Beijing, China
| | - Tian-Shuo Zhao
- Department of Laboratorial Science and Technology, School of Public Health, Peking University, Beijing, China
| | - Jing Zhao
- State Key Laboratory of Pathogen and Biosecurity, Beijing Institute of Microbiology and Epidemiology, Beijing, China
| | - Han-Yu Liu
- Department of Laboratorial Science and Technology, School of Public Health, Peking University, Beijing, China
| | - Juan Du
- Department of Laboratorial Science and Technology, School of Public Health, Peking University, Beijing, China
| | - Ai-Ying Teng
- State Key Laboratory of Pathogen and Biosecurity, Beijing Institute of Microbiology and Epidemiology, Beijing, China
| | - Zi-Wei Zhou
- State Key Laboratory of Pathogen and Biosecurity, Beijing Institute of Microbiology and Epidemiology, Beijing, China
| | - Shi-Xia Zhou
- State Key Laboratory of Pathogen and Biosecurity, Beijing Institute of Microbiology and Epidemiology, Beijing, China
| | - Tian-Le Che
- State Key Laboratory of Pathogen and Biosecurity, Beijing Institute of Microbiology and Epidemiology, Beijing, China
| | - Tao Wang
- State Key Laboratory of Pathogen and Biosecurity, Beijing Institute of Microbiology and Epidemiology, Beijing, China
| | - Tong Yang
- State Key Laboratory of Pathogen and Biosecurity, Beijing Institute of Microbiology and Epidemiology, Beijing, China
| | - Xiu-Gang Guan
- State Key Laboratory of Pathogen and Biosecurity, Beijing Institute of Microbiology and Epidemiology, Beijing, China
| | - Xue-Fang Peng
- State Key Laboratory of Pathogen and Biosecurity, Beijing Institute of Microbiology and Epidemiology, Beijing, China
| | - Yu-Na Wang
- State Key Laboratory of Pathogen and Biosecurity, Beijing Institute of Microbiology and Epidemiology, Beijing, China
| | - Yuan-Yuan Zhang
- State Key Laboratory of Pathogen and Biosecurity, Beijing Institute of Microbiology and Epidemiology, Beijing, China
| | - Shou-Ming Lv
- State Key Laboratory of Pathogen and Biosecurity, Beijing Institute of Microbiology and Epidemiology, Beijing, China
| | - Bao-Cheng Liu
- State Key Laboratory of Pathogen and Biosecurity, Beijing Institute of Microbiology and Epidemiology, Beijing, China
| | - Wen-Qiang Shi
- State Key Laboratory of Pathogen and Biosecurity, Beijing Institute of Microbiology and Epidemiology, Beijing, China
| | - Xiao-Ai Zhang
- State Key Laboratory of Pathogen and Biosecurity, Beijing Institute of Microbiology and Epidemiology, Beijing, China
| | - Xiao-Gang Duan
- School of Statistics, Beijing Normal University, Beijing, China
- These senior authors contributed equally to this manuscript
| | - Wei Liu
- State Key Laboratory of Pathogen and Biosecurity, Beijing Institute of Microbiology and Epidemiology, Beijing, China
- These senior authors contributed equally to this manuscript
| | - Yang Yang
- Department of Biostatistics, College of Public Health and Health Professions, and Emerging Pathogens Institute, University of Florida, Gainesville, United States
- These senior authors contributed equally to this manuscript
| | - Li-Qun Fang
- State Key Laboratory of Pathogen and Biosecurity, Beijing Institute of Microbiology and Epidemiology, Beijing, China
- These senior authors contributed equally to this manuscript
| |
Collapse
|
23
|
Zheng FY, Zhang Y, Zhang LQ, Liu BC, Meng L, Jin J, Liu HL, Sun ZM, Lin LE, Lei PC, Zhu XF, Ma HX, Lu ZS, Jiang H, Zhao YH, Lin H, Zhang X, Yang GP, Zhu HL, Chen SN, You Y, Li WM, Bai QX, Zhao XL, Li ZY, Shen XM, Zhang LP, Jiang Q. [Effect of imatinib on the height of children with chronic myeloid leukemia in the chronic phase]. Zhonghua Xue Ye Xue Za Zhi 2020; 41:545-551. [PMID: 32810960 PMCID: PMC7449767 DOI: 10.3760/cma.j.issn.0253-2727.2020.07.003] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Indexed: 02/05/2023]
Abstract
目的 评估伊马替尼对慢性髓性白血病慢性期(CML-CP)儿童身高的影响。 方法 2018年7月至2019年7月,在全国范围内对诊断时年龄<18周岁、接受伊马替尼治疗至少3个月的CML儿童或其家长发放问卷,调查受访者伊马替尼治疗前后身高的变化。主要评价指标为身高标准差积分值(HtSDS)以及标准差积分的差值(ΔHtSDS),并分析其相关影响因素。 结果 共有238例受访者符合标准并被纳入研究,男性138例(58.0%),初诊时中位年龄11.0(1.4~17.9)岁,青春期前93例(39.0%),至填写答卷时,中位年龄15.0(2.0~34.0)岁,中位伊马替尼服药时间28(3~213)个月。受访者填写答卷时HtSDS(−0.063±1.361)较治疗前HtSDS(0.391±1.244)显著下降(P<0.001),71.0%的患儿出现身高增长减慢。青春期前服药者治疗后HtSDS下降显著(P<0.05),而青春期开始后服药者HtSDS变化不明显(P>0.05)。多因素分析显示,服药初始年龄较小(偏回归系数为0.122,B=0.572,t=10.733,P<0.001)和服药时间较长(偏回归系数为−0.006,B=−0.211,t=−4.062,P<0.001)是伊马替尼抑制身高增长的独立影响因素。 结论 伊马替尼引起CML-CP儿童身高增长障碍,服药初始年龄越小、服药时间越长,伊马替尼对身高的影响越明显。
Collapse
Affiliation(s)
- F Y Zheng
- Peking University People's Hospital, Beijing 100044, China
| | - Yanli Zhang
- Henan Cancer Hospital, Zhengzhou 450008, China
| | - L Q Zhang
- Beijing Children's Hospital Affiliated to Capital Medical University, Beijing 100045, China
| | - B C Liu
- Institute of Hematology and Blood Diseases Hospital, CAMS & PUMC, Tianjin 300020, China
| | - L Meng
- Tongji Hospital Affiliated to Huazhong University of Science and Technology, Wuhan 430030, China
| | - J Jin
- The First Affiliated Hospital of Medical School of Zhejiang University, Hangzhou 310003, China
| | - H L Liu
- Affiliated Provincial Hospital of Anhui Medical University, Hefei 230001, China
| | - Z M Sun
- Affiliated Provincial Hospital of Anhui Medical University, Hefei 230001, China
| | - L E Lin
- Hainan General Hospital, Haikou 570311, China
| | - P C Lei
- Henan Provincial People's Hospital, Zhengzhou 450003, China
| | - X F Zhu
- Institute of Hematology and Blood Diseases Hospital, CAMS & PUMC, Tianjin 300020, China
| | - H X Ma
- The Third Hospital of Zhengzhou, Zhengzhou 450003, China
| | - Z S Lu
- Guangdong General Hospital, Guangzhou 510080, China
| | - H Jiang
- Guangzhou Women and Children's Medical Center, Guangzhou 510623, China
| | - Y H Zhao
- The First Affiliated Hospital of Harbin Medical University, Harbin 150001, China
| | - H Lin
- Jilin University First Hospital, Changchun 130021, China
| | - X Zhang
- Maoming People's Hospital, Maoming 525000, China
| | - G P Yang
- The First Affiliated Hospital of Nanchang University, Nanchang 330006, China
| | - H L Zhu
- West China Hospital of Sichuan University, Chengdu 610041, China
| | - S N Chen
- The First Affiliated Hospital of Soochow University, Suzhou 215006, China
| | - Y You
- Union Hospital Affiliated to Huazhong University of Science and Technology, Wuhan 430022, China
| | - W M Li
- Union Hospital Affiliated to Huazhong University of Science and Technology, Wuhan 430022, China
| | - Q X Bai
- Xijing Hospital of Air Force Medical University, Xi'an 710032, China
| | - X L Zhao
- Xiangya Hospital of Central South University, Changsha 410008, China
| | - Z Y Li
- Affiliated Hospital of Xuzhou Medical University, Xuzhou 221002, China
| | - X M Shen
- The First People's Hospital of Yunnan Province, Kunming 650034, China
| | - L P Zhang
- Peking University People's Hospital, Beijing 100044, China
| | - Q Jiang
- Peking University People's Hospital, Beijing 100044, China
| |
Collapse
|
24
|
Li Y, Gong XY, Zhao XL, Wei H, Wang Y, Lin D, Zhou CL, Liu BC, Wang HJ, Li CW, Li QH, Gong BF, Liu YT, Wei SN, Zhang GJ, Mi YC, Wang JX, Liu KQ. [Rituximab combined with short-course and intensive regimen for Burkitt leukemia: efficacy and safety analysis]. Zhonghua Xue Ye Xue Za Zhi 2020; 41:502-505. [PMID: 32654465 PMCID: PMC7378285 DOI: 10.3760/cma.j.issn.0253-2727.2020.06.012] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Download PDF] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Abstract
目的 探讨利妥昔单抗联合短疗程、高强度方案治疗成人Burkitt白血病患者的疗效和安全性。 方法 收集2006年1月30日至2018年9月12日中国医学科学院血液病医院收治的11例Burkitt白血病患者病例资料,分析统计患者的临床特征、完全缓解(CR)率、总生存率、无复发生存率及不良事件。 结果 11例患者中位年龄34(15~54)岁,其中男6例,女5例。发病时中位WBC 12.28(2.21~48.46)×109/L,HGB 113(74~147)g/L,PLT 35(13~172)×109/L,乳酸脱氢酶2 721(803~17 370)U/L,外周血中位原始细胞比例0.40(0.03~0.76),骨髓中位原始细胞比例0.840(0.295~0.945)。10例患者接受利妥昔单抗联合短疗程、高强度化疗,其中2例患者巩固化疗后行自体造血干细胞移植。所有治疗患者1个疗程CR率为100%,4年总生存率为90%,4年无复发生存率为90%。所有治疗患者中,只有1例患者在诱导化疗中出现肿瘤溶解综合征,经血液透析等治疗后肾功能恢复。无治疗相关性死亡病例。 结论 利妥昔单抗联合短疗程、高强度方案治疗成人Burkitt白血病疗效及安全性均较为理想。
Collapse
Affiliation(s)
- Y Li
- Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College; State Key Laboratory of Experimental Hematology; National Clinical Research Center for Blood Diseases, Tianjin 300020, China
| | - X Y Gong
- Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College; State Key Laboratory of Experimental Hematology; National Clinical Research Center for Blood Diseases, Tianjin 300020, China
| | - X L Zhao
- Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College; State Key Laboratory of Experimental Hematology; National Clinical Research Center for Blood Diseases, Tianjin 300020, China
| | - H Wei
- Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College; State Key Laboratory of Experimental Hematology; National Clinical Research Center for Blood Diseases, Tianjin 300020, China
| | - Y Wang
- Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College; State Key Laboratory of Experimental Hematology; National Clinical Research Center for Blood Diseases, Tianjin 300020, China
| | - D Lin
- Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College; State Key Laboratory of Experimental Hematology; National Clinical Research Center for Blood Diseases, Tianjin 300020, China
| | - C L Zhou
- Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College; State Key Laboratory of Experimental Hematology; National Clinical Research Center for Blood Diseases, Tianjin 300020, China
| | - B C Liu
- Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College; State Key Laboratory of Experimental Hematology; National Clinical Research Center for Blood Diseases, Tianjin 300020, China
| | - H J Wang
- Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College; State Key Laboratory of Experimental Hematology; National Clinical Research Center for Blood Diseases, Tianjin 300020, China
| | - C W Li
- Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College; State Key Laboratory of Experimental Hematology; National Clinical Research Center for Blood Diseases, Tianjin 300020, China
| | - Q H Li
- Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College; State Key Laboratory of Experimental Hematology; National Clinical Research Center for Blood Diseases, Tianjin 300020, China
| | - B F Gong
- Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College; State Key Laboratory of Experimental Hematology; National Clinical Research Center for Blood Diseases, Tianjin 300020, China
| | - Y T Liu
- Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College; State Key Laboratory of Experimental Hematology; National Clinical Research Center for Blood Diseases, Tianjin 300020, China
| | - S N Wei
- Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College; State Key Laboratory of Experimental Hematology; National Clinical Research Center for Blood Diseases, Tianjin 300020, China
| | - G J Zhang
- Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College; State Key Laboratory of Experimental Hematology; National Clinical Research Center for Blood Diseases, Tianjin 300020, China
| | - Y C Mi
- Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College; State Key Laboratory of Experimental Hematology; National Clinical Research Center for Blood Diseases, Tianjin 300020, China
| | - J X Wang
- Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College; State Key Laboratory of Experimental Hematology; National Clinical Research Center for Blood Diseases, Tianjin 300020, China
| | - K Q Liu
- Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College; State Key Laboratory of Experimental Hematology; National Clinical Research Center for Blood Diseases, Tianjin 300020, China
| |
Collapse
|
25
|
Gu Z, Bi Y, Yuan F, Wang R, Li D, Wang J, Hu X, He G, Zhang L, Liu BC. FTO Polymorphisms are Associated with Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD) Susceptibility in the Older Chinese Han Population. Clin Interv Aging 2020; 15:1333-1341. [PMID: 32848374 PMCID: PMC7429205 DOI: 10.2147/cia.s254740] [Citation(s) in RCA: 10] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/01/2020] [Accepted: 06/26/2020] [Indexed: 01/06/2023] Open
Abstract
Background As fat and obesity play a vital role in the pathophysiology of metabolic dysfunction-associated fatty liver disease (MAFLD), this study aims to investigate the association between the fat mass and obesity-associated gene (FTO) and MAFLD. Methods Six SNPs (rs6499640, rs1421085, rs8050136, rs3751812, rs9939609 and rs9930506) within FTO were genotyped for 741 MAFLD patients (median age, 69.98; interquartile range, 66.55–75.93) and 825 healthy people (median age, 69.94; interquartile range, 66.39–75.64). Allele and genotype frequencies, pairwise linkage disequilibrium (LD) and haplotype analysis were calculated. Results BMI, waist circumference, systolic blood pressure, diastolic blood pressure, fasting plasma glucose, triglyceride, alanine transaminase, glutamyl transpeptidase and the prevalence of diabetes were found to be higher in the MAFLD individuals comparing to the control ones (P < 0.05). For rs1421085, the C allele frequency was remarkably higher in MAFLD after Bonferroni correction (OR [95% CI] =1.353 [1.095–1.671]; Pcorr =0.030), and a significantly different genotype result was observed in log-additive model (OR [95% CI] =1.369 [1.108–1.691]; Pcorr =0.024). For rs8050136, significantly increased A allele frequency was observed in MAFLD (OR [95% CI] =1.371 [1.109–1.695]; Pcorr =0.024), and A-allele carriers showed increased MAFLD risk (OR [95% CI] =1.393 [1.103–1.759]; Pcorr =0.030). For rs3751812, the T allele frequency was remarkably higher in MAFLD (OR [95% CI] =1.369 [1.108–1.691]; Pcorr =0.024), and T-allele carriers demonstrated high MAFLD risk (OR [95% CI] =1.392 [1.103–1.756]; Pcorr =0.030). For rs9939609, A allele frequency was also remarkably high in MAFLD (OR [95% CI] =1.369 [1.108–1.691]; Pcorr =0.024), and A-allele carriers were more susceptible to MAFLD (OR [95% CI] =[1.103–1.756]; Pcorr =0.030). A strong LD was found among rs1421085, rs8050136, rs3751812 and rs9939609 (r2 >0.8), and individuals with C-A-T-A haplotype had an elevated MAFLD risk (P =0.005). Conclusion The case-control study indicated that C variant of rs1421085, A variant of rs8050136, T variant of rs3751812 and A variant of rs9939609 are associated with elevated MAFLD risk in the older Chinese Han population.
Collapse
Affiliation(s)
- Zhan Gu
- Shanghai Innovation Center of TCM Health Service, Shanghai University of Traditional Chinese Medicine, Shanghai 201203, People's Republic of China
| | - Yan Bi
- Bio-X Institutes, Key Laboratory for the Genetics of Developmental and Neuropsychiatric Disorders (Ministry of Education), Shanghai Jiao Tong University, Shanghai 200030, People's Republic of China
| | - Fan Yuan
- Bio-X Institutes, Key Laboratory for the Genetics of Developmental and Neuropsychiatric Disorders (Ministry of Education), Shanghai Jiao Tong University, Shanghai 200030, People's Republic of China
| | - Ruirui Wang
- Shanghai Innovation Center of TCM Health Service, Shanghai University of Traditional Chinese Medicine, Shanghai 201203, People's Republic of China
| | - Dong Li
- Zhangjiang Community Health Service Center of Pudong New District, Shanghai, People's Republic of China
| | - Jianying Wang
- Shanghai Innovation Center of TCM Health Service, Shanghai University of Traditional Chinese Medicine, Shanghai 201203, People's Republic of China
| | - Xiaojuan Hu
- Shanghai Innovation Center of TCM Health Service, Shanghai University of Traditional Chinese Medicine, Shanghai 201203, People's Republic of China
| | - Guang He
- Bio-X Institutes, Key Laboratory for the Genetics of Developmental and Neuropsychiatric Disorders (Ministry of Education), Shanghai Jiao Tong University, Shanghai 200030, People's Republic of China
| | - Lei Zhang
- Shanghai Innovation Center of TCM Health Service, Shanghai University of Traditional Chinese Medicine, Shanghai 201203, People's Republic of China
| | - Bao-Cheng Liu
- Shanghai Innovation Center of TCM Health Service, Shanghai University of Traditional Chinese Medicine, Shanghai 201203, People's Republic of China
| |
Collapse
|
26
|
Zheng XW, Zhang L, Zhang WY, Zhang Y, Wang JY, Liu BC, Hu XJ, Hong YL, Yang YQ. Two new xanthones, a new lignin, and twenty phenolic compounds from Smilax china and their NO production inhibitory activities. J Asian Nat Prod Res 2020; 22:509-520. [PMID: 30963782 DOI: 10.1080/10286020.2019.1598395] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 12/19/2018] [Revised: 03/17/2019] [Accepted: 03/18/2019] [Indexed: 06/09/2023]
Abstract
Two new xanthones smilone A (1), smilone B (2), and a new lignin smilgnin A (3) were isolated from the rhizomes of Smilax china L., together with three known xanthones (4-6), four lignins (7-10), two flavones (11, 12), two stilbenoids (13, 14), and ten organic phenoloids (15-24). Of them, compounds 4-6 were isolated from the genus Smilax for the first time. The structures of 1-24 were elucidated by the extensive analysis of spectral data and compared with the literature. All compounds were evaluated for their inhibitory effects against LPS-induced NO production in RAW264.7 macrophages. Among them, compound 24 exhibited significant inhibitory activity against NO production (IC50 = 1.26 µM), while compounds 3, 6, and 7 showed weak activities at the concentration of 50 μM.[Formula: see text].
Collapse
Affiliation(s)
- Xiang-Wei Zheng
- Engineering Research Center of Modern Preparation Technology of TCM, Ministry of Education, Shanghai University of Traditional Chinese Medicine, Shanghai 200000, China
| | - Lei Zhang
- Shanghai Innovation Center of Traditional Chinese Medicine Health Service, Shanghai University of Traditional Chinese Medicine, Shanghai 200000, China
| | - Wei-Yue Zhang
- School of Pharmacy, Shanghai Jiao Tong University, Shanghai 200000, China
| | - Yan Zhang
- School of Pharmacy, Shanghai Jiao Tong University, Shanghai 200000, China
| | - Jian-Ying Wang
- Shanghai Innovation Center of Traditional Chinese Medicine Health Service, Shanghai University of Traditional Chinese Medicine, Shanghai 200000, China
| | - Bao-Cheng Liu
- Shanghai Innovation Center of Traditional Chinese Medicine Health Service, Shanghai University of Traditional Chinese Medicine, Shanghai 200000, China
| | - Xiao-Juan Hu
- Shanghai Innovation Center of Traditional Chinese Medicine Health Service, Shanghai University of Traditional Chinese Medicine, Shanghai 200000, China
| | - Yan-Long Hong
- Shanghai Innovation Center of Traditional Chinese Medicine Health Service, Shanghai University of Traditional Chinese Medicine, Shanghai 200000, China
| | - Yong-Qing Yang
- Yue Yang Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai 200000, China
| |
Collapse
|
27
|
Gu Z, Wang Q, He HY, Li D, Wang RR, Zhang L, Ji G, Liu BC. Genetic variations associated with spleen-yang deficiency pattern of non-alcoholic fatty liver disease: A candidate gene study. Eur J Integr Med 2020. [DOI: 10.1016/j.eujim.2019.101044] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
|
28
|
Wang XY, Ding WW, Liu BC, Sun SL, Fan XX, Wu XJ, Li JS. [Relative factors of transmural intestinal necrosis in acute superior mesenteric vein thrombosis]. Zhonghua Wai Ke Za Zhi 2019; 57:44-50. [PMID: 31510732 DOI: 10.3760/cma.j.issn.0529-5815.2019.10.009] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
Abstract
Objective: To examine the relative factors of transmural intestinal necrosis (TIN) during multidisciplinary stepwise management facilitating the decision making in patients with acute superior mesenteric vein thrombosis (ASMVT). Methods: Clinical data of patients with ASMVT admitted to Department of General Surgery, Jinling Hospital from January 2009 to June 2017 were reviewed retrospectively. There were 52 males and 37 females, aging (45.9 ± 12.6) years (range: 20 to 69 years). According to the postoperative pathological results and follow-up, the patients were divided into TIN group (n=31) and non-TIN group (n=58, including 18 cases of intestinal stricture). The related factors were compared between ASMVT patients with TIN and patients without TIN by univariate analysis using t test, U test and χ(2) test accordingly, and factors with statistically significance were subsequently submitted to binary Logistic regression analysis. The predictive value and cut-off point of factors were evaluated by receiver operator characteristic (ROC) curve and area under the curve. Results: In univariate analysis, smoking, hypertension, peritonitis, white blood cell count,haemoglobin, international normalized ratio, blood albumin, thrombosis of superior mesenteric branches vein, free intraperitoneal fluid, decrease of bowel wall enhancement and pneumatosis intestinalis were TIN risk factors (all P<0.05). According to the binary Logistic regression analysis, white blood cell count (OR=1.093, 95%CI: 1.010 to 1.182, P=0.027), thrombosis of the superior mesenteric branches vein (OR=11.519, 95%CI: 1.906 to 69.615, P=0.008), pneumatosis intestinalis (OR=11.140, 95%CI: 2.360 to 52.585, P=0.002) were independent relative factors of TIN in patients with AMI, and the area under the ROC curve of the above factors and predictive model was 0.759 (95%CI: 0.647 to 0.871), 0.745 (95%CI: 0.641 to 0.848), 0.737 (95%CI: 0.621 to 0.854), 0.909 (95%CI: 0.847 to 0.971), respectively. The cutoff value of white blood cell count was 18.1 × 10(9)/L. Conclusion: White blood cell levels, superior mesenteric vein branch thrombosis and pneumatosis intestinalis are independent predictors of TIN in ASMVT.
Collapse
Affiliation(s)
- X Y Wang
- Department of General Surgery, Jinling Hospital, Medical School of Nanjing University, Research Institute of General Surgery of People's Liberation Army, Nanjing 210002, China
| | | | | | | | | | | | | |
Collapse
|
29
|
Liu KQ, Wang Y, Zhao Z, Lin D, Zhou CL, Liu BC, Gong XY, Zhao XL, Wei SN, Zhang GJ, Gong BF, Li Y, Liu YT, Mi YC, Wang JX, Wei H. [A single-center, randomized controlled trial of PEG-rhG-CSF and common rhG-CSF to promote neutrophil recovery after induction chemotherapy in newly diagnosed acute myeloid leukemia]. Zhonghua Xue Ye Xue Za Zhi 2019; 40:497-501. [PMID: 31340623 PMCID: PMC7342402 DOI: 10.3760/cma.j.issn.0253-2727.2019.06.009] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Indexed: 11/06/2022]
Abstract
目的 比较初诊急性髓系白血病(AML)患者诱导化疗后骨髓抑制期应用聚乙二醇化重组人G-CSF(PEG-rhG-CSF)与普通重组人G-CSF(rhG-CSF)促进中性粒细胞或白细胞恢复的时间。同时比较两种药物对患者感染发生率、住院时间的影响。 方法 采用前瞻性随机对照研究方法,将2014年8月至2017年12月间符合入组条件的初诊AML患者诱导治疗后按1∶1比例随机分成两组:PEG-rhG-CSF组和rhG-CSF组。对比分析两组患者中性粒细胞计数(ANC)或WBC恢复时间、感染发生率和住院时间。 结果 共入组初诊AML患者60例,PEG-rhG-CSF组30例,rhG-CSF组30例。两组患者除性别构成外,在年龄、化疗方案、化疗前ANC、WBC、诱导化疗疗效方面差异均无统计学意义(P值均>0.05)。PEG-rhG-CSF组患者与rhG-CSF组患者的ANC、WBC恢复中位时间分别为19(14~35)d、19(15~26)d,差异无统计学意义(t=0.580,P=0.566)。PEG-rhG-CSF组、rhG-CSF组患者骨髓抑制期感染的发生率分别为90.0%、93.3%,差异无统计学意义(P=1.000)。两组患者的中位住院时间分别为20.5(17~49)d、21(19~43)d,差异无统计学意义(P=0.530)。 结论 AML患者诱导治疗后应用PEG-rhG-CSF与rhG-CSF无论在ANC或WBC恢复时间,还是在感染的发生率及住院时间均相当。
Collapse
Affiliation(s)
- K Q Liu
- Institute of Hematology and Blood Diseases Hospital, CAMS & PUMC, Tianjin 300020, China
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
30
|
Wang RR, Xu YS, Ji MM, Zhang L, Li D, Lang Q, Zhang L, Ji G, Liu BC. Association of the oral microbiome with the progression of impaired fasting glucose in a Chinese elderly population. J Oral Microbiol 2019; 11:1605789. [PMID: 31069021 PMCID: PMC6493323 DOI: 10.1080/20002297.2019.1605789] [Citation(s) in RCA: 22] [Impact Index Per Article: 4.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/06/2019] [Revised: 03/30/2019] [Accepted: 04/03/2019] [Indexed: 01/03/2023] Open
Abstract
Objective: The oral microbiota is associated with the risk of type 2 diabetes (T2D), but the relationship between the oral microbiota and disease progression in the elderly population remains to be determined. Design: In our study, we recruited 150 elderly Chinese residents and divided them into three groups according to their fasting glucose (FG) level: normal (N), high (H), and very high (VH). Their biochemical indexes were analyzed using blood samples. Saliva samples were collected and the oral microbiome was profiled by high-throughput sequencing of the V3-V4 area of the 16S rRNA gene. Result: Our results revealed that the VH group showed deterioration of the metabolic phenotype and dysbiosis of the oral microbiota simultaneously when compared to the other two groups. Furthermore, potential disease-associated bacterial genera including Leptotrichia, Staphylococcus, Catonella, and Bulleidia were significantly enriched in the VH group. Conclusions: These results suggest that dysbiosis of the oral microbiota may be a typical feature of hyperglycemia and might also contribute to disease aggravation in the progression of hyperglycemias.
Collapse
Affiliation(s)
- Rui-Rui Wang
- Shanghai Innovation Center of TCM Health Service, Shanghai University of Traditional Chinese Medicine, Shanghai, China
| | - Yue-Song Xu
- Shanghai Innovation Center of TCM Health Service, Shanghai University of Traditional Chinese Medicine, Shanghai, China
| | - Meng-Meng Ji
- Shanghai Innovation Center of TCM Health Service, Shanghai University of Traditional Chinese Medicine, Shanghai, China
| | - Li Zhang
- Shanghai Innovation Center of TCM Health Service, Shanghai University of Traditional Chinese Medicine, Shanghai, China
| | - Dong Li
- General Practition Department, Zhangjiang Community Health Service Center of Pudong New District, Shanghai, China
| | - Qing Lang
- Traditional Chinese Medicine Department, Beicai Community Health Service Center of Pudong New District, Shanghai, China
| | - Lei Zhang
- Shanghai Innovation Center of TCM Health Service, Shanghai University of Traditional Chinese Medicine, Shanghai, China
| | - Guang Ji
- Shanghai Innovation Center of TCM Health Service, Shanghai University of Traditional Chinese Medicine, Shanghai, China.,Institute of Digestive Diseases, Longhua Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai, China
| | - Bao-Cheng Liu
- Shanghai Innovation Center of TCM Health Service, Shanghai University of Traditional Chinese Medicine, Shanghai, China
| |
Collapse
|
31
|
Affiliation(s)
- D Yang
- Department of Respiratory and Critical Care Medicine, West China School of Medicine and West China Hospital, Sichuan University, No.37 Guoxue Alley, Chengdu, China
| | - B C Liu
- Department of Respiratory and Critical Care Medicine, West China School of Medicine and West China Hospital, Sichuan University, No.37 Guoxue Alley, Chengdu, China
| | - J Luo
- Department of Respiratory and Critical Care Medicine, West China School of Medicine and West China Hospital, Sichuan University, No.37 Guoxue Alley, Chengdu, China
| | - T X Huang
- Department of Respiratory and Critical Care Medicine, West China School of Medicine and West China Hospital, Sichuan University, No.37 Guoxue Alley, Chengdu, China
| | - C T Liu
- Department of Respiratory and Critical Care Medicine, West China School of Medicine and West China Hospital, Sichuan University, No.37 Guoxue Alley, Chengdu, China
| |
Collapse
|
32
|
Liu KQ, Wei H, Lin D, Wang Y, Zhou CL, Liu BC, Li XL, Zhao Y, Li HJ, Wang CW, Li QH, Li BF, Gong YT, Liu XY, Gong YC, Mi JX, Wang J. [Clinical significance of minimal residual disease in patients with Ph-negative precursor B-acute lymphoblastic leukemia]. Zhonghua Xue Ye Xue Za Zhi 2019; 39:724-728. [PMID: 30369181 PMCID: PMC7342254 DOI: 10.3760/cma.j.issn.0253-2727.2018.09.004] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Indexed: 12/31/2022]
Abstract
目的 探讨微小残留病(MRD)水平在Ph染色体阴性的急性B淋巴细胞白血病(Ph− B-ALL)中的预后意义。 方法 采用多色流式细胞术对2010年9月至2017年11月初诊的193例Ph− B-ALL患者在治疗后1、3、6个月进行骨髓MRD监测,并对不同MRD水平患者的预后进行比较。 结果 中位随访22(1~92)个月,所有193例患者共行497次MRD检测。1个月时MRD水平<0.1%和≥0.1%患者的3年预期无复发生存(RFS)率分别为74.5%和29.9%,3年预期总生存(OS)率分别为67.5%和30.3%;3个月时MRD水平阴性和阳性患者的3年预期RFS率分别为75.6%和29.7%,3年预期OS率分别为71.6%和27.8%;6个月时MRD水平阴性或阳性患者的3年预期RFS率分别为74.6%和11.6%,3年预期OS率分别为74.0%和15.7%,差异均有统计学意义(P值均<0.001)。3个监测点全部达到MRD阴性标准的患者与至少1次未达到MRD阴性标准的患者比较,3年预期RFS、OS率差异均有统计学意义(80.5%对30.5%,77.1%对29.4%,P值均<0.001)。多因素分析结果显示,3个月时的MRD水平是Ph− B-ALL患者独立的预后因素之一。 结论 治疗后MRD监测对Ph− B-ALL的预后判断有重要意义。
Collapse
Affiliation(s)
- K Q Liu
- Institute of Hematology and Blood Diseases Hospital, CAMS & PUMC, Tianjin 300020, China
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
33
|
Gu RX, Wei H, Wang Y, Liu BC, Zhou CL, Lin D, Liu KQ, Wei SN, Gong BF, Zhang GJ, Liu YT, Zhao XL, Gong XY, Li Y, Qiu SW, Mi YC, Wang JX. [Impact of duration of antibiotic therapy on the prognosis of patients with acute myeloid leukemia who had Gram-negative bloodstream infection in consolidation chemotherapy]. Zhonghua Xue Ye Xue Za Zhi 2019; 39:471-475. [PMID: 30032562 PMCID: PMC7342929 DOI: 10.3760/cma.j.issn.0253-2727.2018.06.006] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Download PDF] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
目的 分析巩固化疗期间伴发革兰阴性菌(G−菌)血流感染的急性髓系白血病(AML)患者抗感染疗程对感染转归的影响。 方法 回顾性分析2010年9月至2016年1月入组“依据危险度分层对急性髓系白血病优化治疗的研究”临床试验的591例AML(非急性早幼粒细胞白血病)患者的血流感染资料,将其中巩固化疗期间发生G−菌血流感染且持续发热时间<7 d的114例次血流感染(89例患者)纳入研究,分析抗感染疗程对感染转归的影响。 结果 114例次血流感染发生时,患者中位ANC为0(0~5.62)×109/L,中性粒细胞缺乏(粒缺)持续的中位时间为9(3~26)d,抗感染治疗的中位时间为7(4~14)d。抗感染疗程≤7 d与>7 d组比较,停药后3 d内再发热比例、再次发生相同菌株血流感染比例分别为1.2%对3.0%、18.5%对21.2%,差异均无统计学意义(P=0.522,OR=0.400,95%CI 0.024~6.591;P=0.741,OR=0.844,95%CI 0.309~2.307)。同时,两组患者均未发生7 d及30 d内感染相关死亡。且倾向性评分平衡患者特征及用药差异因素后,抗感染疗程≤7 d较>7 d组再次发生相同菌株血流感染比例仍无明显增高(P=0.525,OR=0.663,95%CI 0.187~2.352)。 结论 对于巩固化疗期间伴发G−菌血流感染的AML患者,若发热时间<7 d,敏感抗菌药物治疗7 d后停药并不增加停药后3 d内再发热,粒缺期再次出现相同菌株血流感染及感染相关7 d、30 d内死亡风险。提示短疗程抗感染方案可以成为巩固化疗伴发G−菌血流感染AML患者感染控制情况下合理的治疗选择。
Collapse
Affiliation(s)
- R X Gu
- Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin 300020, China
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
34
|
Zhu XJ, You Y, Duan MH, Zhu Y, Liu BC, Chen SN, Du X. [Tyrosine kinase inhibitors discontinuation for chronic myeloid leukemia: a multicenter retrospective analysis in China]. Zhonghua Xue Ye Xue Za Zhi 2019; 39:994-997. [PMID: 30612400 PMCID: PMC7348222 DOI: 10.3760/cma.j.issn.0253-2727.2018.12.005] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Indexed: 11/10/2022]
Abstract
目的 回顾性分析中国慢性髓性白血病(CML)酪氨酸激酶抑制剂(TKI)自动停药患者的临床特征及转归情况。 方法 回顾性分析2005年6月1日至2018年3月1日国内7家单位109例自动停用TKI的慢性期CML患者临床资料,将其中具有明确停药结局及相对完整临床资料的91例患者进行统计分析,观察患者自动停药后获得无治疗缓解(TFR)情况及其影响因素。 结果 91例患者累积服用TKI中位时间为65(7~138)个月,其中21例患者有减停药史;患者达到主要分子学缓解(MMR)中位时间为开始服用TKI后6(3~57)个月;全部患者停药前达MR4.0。停药后中位随访9(1~72)个月,53例(58.2%)患者继续维持MMR,获得TFR;38例(41.8%)失去MMR。12个月和25个月的TFR率分别为61.4%和52.6%。31例停药后复发的患者再启动药物治疗,用药后再获得MMR的中位时间为3(1~12)个月。对比分析发现,Sokal评分(P=0.294)、累积服用TKI时间(P=0.827)、获得MMR所需时间(P=0.553),是否减停TKI(P=0.125)等因素对复发无明显影响。而停药前MMR维持时间越长(≥24个月)患者后期复发率越低(P=0.027)。 结论 达停药标准的中国CML患者能够安全停用TKI,停药后TFR率与国外报道相当。停药前MMR时间维持越长,停药后复发率越低。
Collapse
Affiliation(s)
| | | | | | | | | | - S N Chen
- First Affiliated Hospital of Soochow University, Suzhou 215006, China
| | - X Du
- the Second People's Hospital of Shenzhen, Shenzhen 518035, China
| |
Collapse
|
35
|
Gong BF, Liu YT, Zhang GJ, Wei SN, Li Y, Liu KQ, Gong XY, Zhao XL, Qiu SW, Gu RX, Lin D, Wei H, Zhou CL, Liu BC, Wang Y, Mi YC, Wang JX. [Primary antifungal prophylaxis with posaconazole plays a pivotal role during chemotherapy of acute myeloid leukemia]. Zhonghua Xue Ye Xue Za Zhi 2018; 38:528-531. [PMID: 28655098 PMCID: PMC7342978 DOI: 10.3760/cma.j.issn.0253-2727.2017.06.012] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Download PDF] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
Abstract
Objective: To evaluate the incidence of invasive fungal infections (IFI) and usage of intravenous antifungal drugs during remission induction chemotherapy in patients with acute myeloid leukemia (AML) under primary antifungal prophylaxis with posaconazole. Methods: Clinical records from newly diagnosed AML patients above 15 years old in one single center from February 2014 to January 2016 were retrospectively reviewed and analyzed, excluding acute promyelocytic leukemia. The incidence of IFI and usage of intravenous antifungal drugs were investigated between control group (not receiving any broad spectrum antifungal prophylaxis) and treatment group (receiving posaconazole as primary prophylaxis). Results: A total of 147 newly diagnosed AML patients were enrolled. Of them, 81 received prophylaxis with posaconazole, and 66 did not receive broad-spectrum antifungal treatment. 7 IFI occurred in posaconazole group, and all were possible cases; 19 IFI occurred in control group (3 proven, 4 probable, 12 possible). The incidence of IFI was significantly lower in treatment group than that in control group (8.6% vs 28.8%, χ(2)=10.138, P=0.001). Usage of intravenous antifungal drugs was significantly decreased in posaconazole group (18.5% vs 50.0%, χ(2)=16.390, P<0.001). Conclusion: Prophylaxis with posaconazole coulf prevent IFI and reduce usage of intravenous antifungal drugs significantly during remission induction chemotherapy in AML patients.
Collapse
Affiliation(s)
- B F Gong
- Institute of Hematology & Blood Diseases Hospital, CAMS & PUMC, Tianjin Clinical Research Center for Blood Diseases, Tianjin 300020, China
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
36
|
Wan YL, Wang Y, Liu BC, Liu X, Gong XY, Zhao XL, Wang TY, Jiang EL, Feng SZ, Han MZ, Qiu LG, Mi YC, Wang JX. [Application of imatinib in BCR- ABL positive acute lymphoblastic leukemia treatment in the real world]. Zhonghua Xue Ye Xue Za Zhi 2018; 37:886-891. [PMID: 27801322 PMCID: PMC7364881 DOI: 10.3760/cma.j.issn.0253-2727.2016.10.014] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Download PDF] [Subscribe] [Scholar Register] [Indexed: 12/11/2022]
Abstract
目的 探讨真实世界中伊马替尼(IM)联合化疗治疗BCR-ABL阳性急性淋巴细胞白血病(ALL)的疗效及相关预后因素。 方法 2003年4月至2015年8月收治的209例治疗中包含IM的BCR-ABL阳性ALL患者纳入研究,106例患者接受造血干细胞移植(HSCT)。对患者的疗效和预后影响因素进行分析。 结果 初诊患者诱导完全缓解(CR)率为97.9%。初诊时WBC≥100×109/L是总生存(OS)的不良预后因素(P=0.043)。未接受HSCT、诱导治疗4周内未达CR和治疗过程中未达到分子生物学完全缓解(CMR)是OS(P值分别为<0.001、0.009和<0.001)和无复发生存(RFS)(P值均<0.001)的不良预后因素。接受异基因HSCT和自体HSCT的患者,其OS和RFS的差异均无统计学意义(P值均>0.05)。首次诱导治疗时联用IM的患者较未联用者显示出更高的5年RFS率(37.0%对24.0%,P= 0.005)。在治疗过程中持续规律服用酪氨酸激酶抑制剂(TKI,40例患者由于复发、转录本水平下降不理想或出现突变换用其他TKI)的患者生存情况最佳,其次为骨髓抑制期间断停用TKI的患者,不规律服用TKI的患者生存情况最差,三组5年OS率分别为46.0%、28.0%、17.0%(P=0.004),5年RFS率分别为38.0%、28.0%、17.0%(P<0.001)。 结论 TKI联合化疗获得CMR,序贯以HSCT可改善BCR-ABL阳性ALL患者预后,持续规律地联用TKI有助于BCR-ABL阳性ALL患者疗效的提高。
Collapse
Affiliation(s)
- Y L Wan
- Institute of Hematology & Blood Diseases Hospital, CAMS & PUMC, Tianjin 300020, China
| | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
37
|
Gong XY, Wang Y, Liu BC, Wei H, Li CW, Li QH, Zhao JW, Zhou CL, Lin D, Liu KQ, Wei SN, Gong BF, Zhang GJ, Liu YT, Zhao XL, Li Y, Gu RX, Qiu SW, Mi YC, Wang JX. [Characteristics and prognosis in adult acute myeloid leukemia patients with MLL gene rearrangements]. Zhonghua Xue Ye Xue Za Zhi 2018; 39:9-14. [PMID: 29551026 PMCID: PMC7343107 DOI: 10.3760/cma.j.issn.0253-2727.2018.01.003] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 07/12/2017] [Indexed: 01/27/2023]
Abstract
Objective: To analyze the clinical and laboratory characteristics, and prognosis of adult acute myeloid leukemia (AML) patients with MLL gene rearrangements. Methods: The medical records of 92 adult AML patients with MLL gene rearrangements from January 2010 to December 2016 were retrospectively analyzed. Results: 92 cases (6.5%) with MLL gene rearrangements were identified in 1 417 adult AML (Non-M(3)) patients, the median age of the patients was 35.5 years (15 to 64 years old) with an equal sex ratio, the median WBC were 21.00(0.42-404.76)×10(9)/L, and 78 patients (84.8%) were acute monoblastic leukemia according to FAB classification. Eleven common partner genes were detected in 32 patients, 9 cases (28.1%) were MLL/AF9(+), 5 cases (15.6%) were MLL/AF6(+), 5 cases (15.6%) were MLL/ELL(+), 2 cases (6.3%) were MLL/AF10(+), 1 case (3.1%) was MLL/SETP6(+), and the remaining 10 patients' partner genes weren't identified. Of 92 patients, 83 cases with a median follow-up of 10.3 (0.3-74.0) months were included for the prognosis analysis, the complete remission (CR) rate was 85.5% (71/83), the median overall survival (OS) and relapse free survival (RFS) were 15.4 and 13.1 months, respectively. Two-year OS and RFS were 36.6% and 29.5%, respectively. Of 31 patients underwent allogeneic hematopoietic stem-cell transplantation (allo-HSCT), two-year OS and RFS for patients received and non-received allo-HSCT were 57.9% and 21.4%, 52.7% and 14.9%, respectively (P<0.001). Among patients with partner genes tested, 9 of 32 cases (28.1%) were MLL/AF9(+), the median follow-up was 6.0(4.1-20.7) months. 3 patients with MLL/AF9 underwent allo-HSCT. 23 cases (71.9%) were non- MLL/AF9(+), the median follow-up was 7.8 (0.3-26.6) months. 14 patients (60.1%) with non-MLL/AF9 underwent allo-HSCT. One-year OS for patients with MLL/AF9 and non-MLL/AF9 were 38.1% and 55.5%, respectively (P=0.688). Multivariate analysis revealed that high WBC (RR=1.825, 95% CI 1.022-3.259, P=0.042), one cycle to achieve CR (RR=0.130, 95% CI 0.063-0.267, P<0.001), post-remission treatment with allo-HSCT (RR=0.169, 95% CI 0.079-0.362, P<0.001) were independent prognostic factors affecting OS. Conclusions: AML with MLL gene rearrangements was closely associated with monocytic differentiation, and MLL/AF9 was the most frequent partner gene. Conventional chemotherapy produced a high response rate, but likely to relapse, allo-HSCT may have the potential to further improve the prognosis of this group of patients.
Collapse
Affiliation(s)
- X Y Gong
- State Key Laboratory of Experimental Hematology, Institute of Hematology and Blood Diseases Hospital, CAMS & PUMC, Tianjin 300020, China
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
38
|
Cheng YS, Chao J, Zhu DD, Liu BC. 14 The mechanism of pkcΒ-p66shc-nadph oxidase pathway in high glucose induced-oxidative stress in renal tubular epithelial cells. J Investig Med 2017. [DOI: 10.1136/jim-2017-mebabstracts.14] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
|
39
|
Peng N, Wei H, Lin D, Zhou CL, Liu BC, Wang Y, Liu KQ, Gong BF, Wei SN, Zhang GJ, Liu YT, Gong XY, Qiu SW, Mi YC, Wang JX. [Prognostic significance of flow cytometric minimal residual disease in acute myeloid leukemia during aplasia]. Zhonghua Xue Ye Xue Za Zhi 2017; 38:767-771. [PMID: 29081193 PMCID: PMC7348354 DOI: 10.3760/cma.j.issn.0253-2727.2017.09.007] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 03/14/2017] [Indexed: 11/16/2022]
Abstract
Objective: To investigate the impact of minimal residual disease (MRD) by multiparameter flow cytometry (MPFC) during aplasia on efficacy and prognosis of de novo acute myeloid leukemia (AML) (non M(3)) patients. Methods: The MRD data by 8-color MPFC during aplasia (day 14-15 of induction therapy) in 85 de novo AML (non M(3)) patients and the MRD impact on efficacy and prognosis were retrospectively analyzed. Results: Data of 85 patients, including 42 males (49.4%) and 43 females (50.6%) , were collected, with a median age of 35 (15-54) years. The median MRD by MPFC during aplasia was 0.58% (0-81.11%) , and 70 (82.4%) patients achieved complete remission (CR) after first induction chemotherapy. The cutoff of MRD by receiver operating characteristic (ROC) analysis was 2.305% (Se= 0.867, Sp=0.800) . The CR rate after one course was significantly higher in patients with MRD<2.305% [96.6% (56/58) ]than in patients with MRD≥2.305%[51.9% (14/27) ] (χ(2)=22.348, P<0.001) ; no significant difference with respect to relapse-free survival rate (χ(2)=1.08, P=0.299) or overall survival rate (χ(2)=0.42, P=0.516) could be demonstrated for the comparison of the two groups. Multivariates analysis showed MRD divided by 2.305% was the only independent prognostic factor for CR after one course (OR= 21.560, 95% CI 4.129-112.579, P<0.001) . Conclusion: Flow cytometric MRD divided by 2.305% during aplasia could be a predictor of efficacy after first induction therapy in AML patients.
Collapse
Affiliation(s)
- N Peng
- Institute of Hematology & Blood Disease Hospital, CAMS & PUMC, Tianjin 300020, China
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
40
|
Zhao N, Wei H, Wang Y, Lin D, Zhou CL, Liu BC, Liu KQ, Zhang GJ, Wei SN, Gong BF, Gong XY, Li W, Li Y, Liu YT, Qiu SW, Gu RX, Mi YC, Wang JX. [Prediction of outcome in acute myeloid leukemia by measurement of WT1 expression as a basic marker of minimal residual disease]. Zhonghua Xue Ye Xue Za Zhi 2017; 38:695-699. [PMID: 28954349 PMCID: PMC7348239 DOI: 10.3760/cma.j.issn.0253-2727.2017.08.009] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 12/27/2016] [Indexed: 11/14/2022]
Abstract
Objective: To probe the potential utility of Wilms tumor 1 (WT1) as a marker of minimal residual disease (MRD) in acute myeloid leukemia (AML) to estimate the relapse-predicting cut-off value. Methods: Quantitative assessment of bone marrow WT1 mRNA level was preformed using real-time quantitative reverse transcription polymerase chain reaction (RQ-RT-PCR) assay. The expression levels of WT1 dynamically measured with RQ-RT-PCR were retrospectively analyzed in 121 AML cases (not including acute promyelocytic leukemia) achieving complete remission (CR) after induction therapy followed by consolidation therapy. By comparing WT1 levels of patients with different post-therapy outcomes, the investigators used the receiver operating characteristic (ROC) curve to determine WT1 threshold so as to predict their clinical relapses. Then prognoses and the significance of intervention were analyzed between WT1 positive and negative patients according to the cut-off value of WT1. Results: According to ROC curve, WT1 level higher than 2.98% predicted the possibility of relapse. For simplicity and clinical application, 3.00% was used as the cut-off value of WT1 level for relapse. WT1 levels in 41 patients at diagnosis were detected, meanwhile 3 patients whose WT1 levels at diagnosis below 3.00% were excluded, then the median WT1 level of the rest 38 patients at diagnosis was 44.09% (range 7.19%-188.06%) . The median WT1 level in remission was 0.48% (352 samples, range 0-8.41%) . The median WT1 level at diagnosis was higher than that in remission. Excluding the 3 patients with WT1 level at diagnosis under 3.00%, the relapse rate of WT1 positive group (>3.00% during consolidation phase and follow-up) and WT1 negative group (≤3.00%) was 70.0% (14/20) and 12.2% (12/98) respectively (P<0.001) . The median time from WT1 positivity to clinical relapse was 58 days. Conclusions: WT1 expression level above 3.00% was associated with markedly high risk of relapse, which could be as a useful marker for monitoring MRD following consolidation therapy.
Collapse
Affiliation(s)
- N Zhao
- Institute of Hematology & Blood Disease Hospital, CAMS & PUMC, Tianjin 300020, China
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
41
|
Liu BC, Ji G. Sparking Thinking: Studying Modern Precision Medicine Will Accelerate the Progression of Traditional Chinese Medicine Patterns. J Altern Complement Med 2017; 23:502-504. [DOI: 10.1089/acm.2016.0383] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/21/2022] Open
Affiliation(s)
- Bao-Cheng Liu
- Shanghai Innovation Center of TCM Health Service, Shanghai University of Traditional Chinese Medicine, Shanghai, China
| | - Guang Ji
- Institute of Digestive Disease, China-Canada Center of Research for Digestive Diseases, Longhua Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai, China
| |
Collapse
|
42
|
Pan MM, Liu BC. [Hypoxia-inducible factors stabilizer: new approach for treatment of renal anemia]. Zhonghua Nei Ke Za Zhi 2017; 56:225-228. [PMID: 28253609 DOI: 10.3760/cma.j.issn.0578-1426.2017.03.018] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/06/2023]
|
43
|
Gong XY, Wang Y, Liu BC, Wei H, Zhou CL, Lin D, Liu KQ, Wei SN, Gong BF, Zhang GJ, Liu YT, Zhao XL, Li Y, Gu RX, Qiu SW, Mi YC, Wang JX. [Clinical features and prognosis in CD10(-) pre-B acute lymphoblastic leukemia]. Zhonghua Xue Ye Xue Za Zhi 2017; 38:17-21. [PMID: 28219219 PMCID: PMC7348396 DOI: 10.3760/cma.j.issn.0253-2727.2017.01.004] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Download PDF] [Subscribe] [Scholar Register] [Indexed: 11/23/2022]
Abstract
目的 分析CD10阴性的前B急性淋巴细胞白血病(CD10−pre B-ALL)患者的临床特征和预后。 方法 对6例成人CD10− pre B-ALL患者的临床和实验室资料进行回顾性分析,结合文献复习明确该类型患者的临床特征及预后。 结果 CD10−pre B-ALL占ALL的1.5%(6/409),占B-ALL的1.8%(6/343),占pre B-ALL的11.5%(6/52)。6例患者均为男性,中位年龄为33.5岁,起病时中位WBC为101.78×109/L,所有患者均伴有MLL-AF4融合基因表达。5例患者经1个疗程诱导化疗即获得完全缓解(CR),1例患者经3个疗程化疗后才获得CR。2例患者在CR1期行异基因造血干细胞移植(allo-HSCT),1例患者CR后短期内即复发,在CR2期行allo-HSCT。1例患者正在等待移植。2例未移植患者1例复发死亡,1例尚处于缓解状态。 结论 CD10−pre B-ALL是一类具有独特临床特征的成人ALL亚型,发生率较低,常见于男性,起病时白细胞水平较高,MLL-AF4融合基因表达率高,常规化疗具有较高的缓解率,但易复发,allo-HSCT有可能改善其预后。
Collapse
Affiliation(s)
- X Y Gong
- Institute of Hematology & Blood Diseases Hospital, CAMS & PUMC, Tianjin 300020, China
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
44
|
Liu BC, Tang TT, Lü LL. [Opportunities and challenges in the study of renal fibrosis in the era of precision medicine]. Zhonghua Yi Xue Za Zhi 2016; 96:3041-3043. [PMID: 27784442 DOI: 10.3760/cma.j.issn.0376-2491.2016.38.001] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Subscribe] [Scholar Register] [Indexed: 06/06/2023]
|
45
|
Sun T, Long H, Liu BC, Li Y. Application of side-oblique image-motion blur correction to Kuaizhou-1 agile optical images. Opt Express 2016; 24:6665-6679. [PMID: 27136855 DOI: 10.1364/oe.24.006665] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/05/2023]
Abstract
Given the recent development of agile optical satellites for rapid-response land observation, side-oblique image-motion (SOIM) detection and blur correction have become increasingly essential for improving the radiometric quality of side-oblique images. The Chinese small-scale agile mapping satellite Kuaizhou-1 (KZ-1) was developed by the Harbin Institute of Technology and launched for multiple emergency applications. Like other agile satellites, KZ-1 suffers from SOIM blur, particularly in captured images with large side-oblique angles. SOIM detection and blur correction are critical for improving the image radiometric accuracy. This study proposes a SOIM restoration method based on segmental point spread function detection. The segment region width is determined by satellite parameters such as speed, height, integration time, and side-oblique angle. The corresponding algorithms and a matrix form are proposed for SOIM blur correction. Radiometric objective evaluation indices are used to assess the restoration quality. Beijing regional images from KZ-1 are used as experimental data. The radiometric quality is found to increase greatly after SOIM correction. Thus, the proposed method effectively corrects image motion for KZ-1 agile optical satellites.
Collapse
|
46
|
Wang Y, Liu BC, Wei H, Lin D, Zhou CL, Liu KQ, Li W, Wei SN, Wang JY, Gong BF, Zhang GJ, Zhao XL, Liu YT, Gong XY, Li Y, Gu RX, Mi YC, Wang JX. [Homoharringtonine in newly diagnosed acute promyelocytic leukemia treatment: a prospective, randomized controlled trial]. Zhonghua Xue Ye Xue Za Zhi 2016; 37:183-8. [PMID: 27033753 PMCID: PMC7342959 DOI: 10.3760/cma.j.issn.0253-2727.2016.03.002] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 10/23/2015] [Indexed: 11/06/2022]
Abstract
OBJECTIVE To compare the efficacy and toxicities of combining homoharringtonine (HHT)±daunorubicin (DNR) with all-trans-retinoic acid (ATRA) based therapy and DNR plus ATRA based therapy in newly diagnosed low/intermediate risk acute promyelocytic leukemia (APL). METHODS A total of 96 newly diagnosed patients with APL were randomized to HHT group, DNR group and HHT+ DNR group prospectively. The complete remission (CR) rate, the overall survival (OS) and event-free survival (EFS) of three groups were analyzed. RESULTS There were 31 patients in HHT group, 33 patients in DNR group and 32 patients in HHT+ DNR group. The baseline characteristics of three groups were similar. No patient died during induction therapy. The morphologic CR rate was 100.0%. The median time to peak WBC counts in HHT+DNR group (4 days, range: 1-23 days) was significantly shorter than that in HHT group (9 days, range: 1-27 days) (P=0.008) and DNR group (7 days, range: 1-27 days) (P=0.240). There was no difference among three groups about the incidence of differentiation syndrome, the median interval to achieve CR, peak WBC counts and transfusions (P >0.05). All patients achieved complete molecular remission (CMR) during consolidation therapy. The interval to achieve CMR was no significantly difference among three groups (P >0.05). The 3-year OS rates for HHT group, DNR group and HHT+DNR group were 95.0%, 100.0% and 91.0%, respectively (P=0.595). The 3-year EFS rates for three groups were 93.0%, 90.0% and 85.0% (P=0.382). No difference was found in the incidence of adverse events among three groups (P >0.05). CONCLUSIONS Similar to DNR plus ATRA based therapy, HHT plus ATRA based induction and consolidation therapy should be one of highly-efficient treatment options for newly diagnosed APL. Clinical trial registration Chinese Clinical Trial Registry, ChiCTR-TRC-12002628.
Collapse
Affiliation(s)
- Y Wang
- Leukemia Center, Institute of Hematology & Blood Disease Hospital, CAMS & PUMC, Tianjin 300020, China
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
47
|
Sun T, Long H, Liu BC, Li Y. Application of attitude jitter detection based on short-time asynchronous images and compensation methods for Chinese mapping satellite-1. Opt Express 2015; 23:1395-1410. [PMID: 25835898 DOI: 10.1364/oe.23.001395] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/04/2023]
Abstract
Given the recent development in high-resolution (HR) optical satellites, the study of both attitude jitter (AJ) detection and compensation has become increasingly essential to improving the radiometric and geometric quality of HR images. A group of HR optical stereo mapping satellites in China, mapping satellite-1 (MS-1) has launched two satellites and will launch one satellite to build a satellite network. The geometric accuracy of the launched MS-1 satellites is greater than 80 m because of the AJ caused by the instability of the platform. AJ detection and compensation are critical issues that must be addressed to improve the accuracy of geo-positioning and mapping before launching a new satellite. The present study employs a method of jitter detection based on short-time asynchronous images to detect MS-1 jitter. The adjacent overlapping areas of an original panchromatic image are used as detection images instead of the traditional multispectral images, and a differential recursion optimal estimation filter is proposed for the optimal estimation and elimination of the gross errors of the registration data procedure, thereby increasing the detection accuracy. The space variant blurring model and viewing angles correction method are employed for the radiometric and geometric jitter compensation of images, respectively. The methods of radiometric objective evaluation indices and geometric checkpoint are then utilised to evaluate the quality of jitter compensation. Finally, the DeZhou regional image (ShanDong province, China) from MS-1 is used as the experimental data. Results for the AJ of MS-1 are analysed and reported for the first time. The assessment results obtained show that both radiometric and geometric qualities greatly increase after the jitter compensation procedure. Thus, the work of this study for jitter detection and compensation effectively addresses the jitter of MS-1 HR optical satellites.
Collapse
|
48
|
Liu BC, Zhu SJ, Liu FQ. 5,6-Dimethyl-1 H-benzimidazol-3-ium nitrate. Acta Crystallogr Sect E Struct Rep Online 2013; 69:o1645. [PMID: 24454088 PMCID: PMC3884312 DOI: 10.1107/s1600536813027578] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/22/2013] [Accepted: 10/09/2013] [Indexed: 11/10/2022]
Abstract
The title salt, C9H11N2+·NO3−, features a planar cation (r.m.s. for 11 non-H atoms = 0.016 Å). In the crystal, N—H...O hydrogen bonds link nitrate and benzimidazole ions into a three-dimensional network.
Collapse
|
49
|
Zhou SL, Yue WB, Fan ZM, Du F, Liu BC, Li B, Han XN, Ku JW, Zhao XK, Zhang P, Cui J, Zhou FY, Zhang LQ, Fan XP, Zhou YF, Zhu LL, Liu HY, Wang LD. Autoantibody detection to tumor-associated antigens of P53, IMP1, P16, cyclin B1, P62, C-myc, Survivn, and Koc for the screening of high-risk subjects and early detection of esophageal squamous cell carcinoma. Dis Esophagus 2013; 27:790-7. [PMID: 24147952 DOI: 10.1111/dote.12145] [Citation(s) in RCA: 25] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/11/2022]
Abstract
The aim of this study was to evaluate the diagnostic values by detecting sera autoantibodies to eight tumor-associated antigens (TAAs) of P53, IMP1, P16, cyclin B1, P62, C-myc, Survivn and Koc full-length recombinant proteins for the screening of high-risk subjects and early detection of esophageal squamous cell carcinoma (ESCC). Enzyme-linked immunosorbent assay was used to detect autoantibodies against the eight selected TAAs in 567 sera samples from four groups, including 200 individuals with normal esophageal epithelia (NOR), 214 patients with esophageal basal cell hyperplasia (BCH), 65 patients with esophageal dysplasia (DYS), and 88 patients with ESCC. In addition, the expression of the eight antigens in esophageal tissues was analyzed by immunohistochemistry. Statistically significant distribution differences were identified among the four groups for each of the individual autoantibodies to six TAAs (P53, IMP1, P16, cyclin B1, P62, and C-myc); the detection rates of antoantibodies were positively correlated with the progression of ESCC. When autoantibody assay successively accumulated to six TAAs (P53, IMP1, P16, cyclin B1, P62, and C-myc), a stepwise increased detection frequency of autoantibodies was found in the four sera groups (6% in NOR, 18% in BCH, 38% in DYS, and 64% in ESCC, respectively), the risks to BHC, DYS, and ESCC steadily increased about 3-, 9-, and 27-folds. The sensitivity and the specificity for autoantibodies against the six TAAs in diagnosing ESCC reached up to 64% and 94%, respectively. The area under the receiver operating characteristic curve for the six anti-TAA autoantibodies was 0.78 (95% confidence interval 0.74-0.83). No more increasing in sensitivity was found with the addition of new anti-TAA autoantibodies. A combination detection of autoantibodies to TAAs might distinguish ESCC patients from normal individuals and the patients with esophageal precancerous lesions.
Collapse
Affiliation(s)
- S L Zhou
- Henan Key Laboratory for Esophageal Cancer Research, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
50
|
Liu BC, Jin YL, Liu FQ. Dibromidobis(2-methyl-1 H-benzimidazole-κ N3)cadmium. Acta Crystallogr Sect E Struct Rep Online 2013; 69:m536. [PMID: 24098169 PMCID: PMC3790347 DOI: 10.1107/s1600536813024549] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/10/2013] [Accepted: 09/03/2013] [Indexed: 11/10/2022]
Abstract
In the title compound, [CdBr2(C8H8N2)2], the CdII atom has a distorted tetrahedral coordination formed by the two imino N atoms of two 2-methylbenzimidazole ligands and two terminal bromide ligands. The CdII atom is slightly out of the benzimidazole planes by 0.320 (3) and 0.210 (3) Å. The dihedral angle between the benzimidazole planes is 71.6 (2)°. In the crystal, molecules are linked by N—H⋯Br hydrogen bonds into puckered layers parallel to (001).
Collapse
|